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ABSTRACT

Glioblastoma (GBM) is the most common and aggressive brain tumor, with very
poor prognosis. Androgen receptor (AR) plays a significant role in the progression of
GBM, and anti-androgen agents have the potential to be used for the treatment of GBM.
However, AR mutation commonly happens in GBM, which makes the anti-androgen

agents less effective. Heat shock 27 kDa protein (HSP27) is a well-documented
chaperone protein to stabilize AR. Inhibition of HSP27 results in AR degradation

regardless the mutation status of AR, which makes HSP27 a good target to abolish AR in
GBM.

Identified compound I ((N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)

phenyl)-4-methoxybenzamide) inhibits GBM cell growth with IC50s around 5 nM, and
also shows significant inhibition in an in vivo GBM xenograft model at 20 mg/kg.

Furthermore, it does not show toxicity to mice up to 80 mg/kg, 4-fold higher than the
active in vivo dose. The compound significantly induces AR degradation in GBM cells
via the proteasomal pathway. These results suggest that targeting HSP27 chaperone

function to induce AR degradation in GBM is a promising and novel treatment.
Additionally, a sensitive and rapid high-performance liquid chromatography

tandem mass spectrometry (HPLC-MS/MS) method was developed and validated to
investigate the pharmacokinetics and brain distribution of compound I in mice. The

v

method was successfully applied to evaluate the pharmacokinetic of compound I in
mouse plasma and brain tissue. The apparent elimination half-life (t1∕2) was 4.06 h. The

Cmax of compound I in brain tissue was 0.88 μg∕g. The results indicated that compound I

was rapidly distributed and compound I could cross the blood-brain barrier (BBB). The
pharmacokinetic profile summarized provides valuable information for the further
investigation of compound I as a potential anti-glioblastoma agent.
Ligand based structural optimization in the project identified two novel compounds

(compounds 4 and 26) which have potent anti-GBM activity and significantly increased

BBB permeability in comparison to the lead compound I. This study indicated that
compounds 4 and 26 could be the promising drugs to treat AR over expressed GBM, also

provided a meaningful insight for the further structural modification to retain or improve
the potency and BBB permeability.
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CHAPTER I

INTRODUCTION

1.1 Glioblastoma
Glioblastoma multiforme (GBM) is the most common and malignant tumor of the
brain, with about 12,000 cases diagnosed in the United States annually 1,2. GBM is also

referred to as a grade IV astrocytoma, a cancer that forms from astrocytes. This type of
cancer usually starts in the cerebrum, the largest part of brain in adults. GBM is a

devastating brain cancer that can result in death in 6 months or less if untreated 3. GBM
has an incidence of 3.21 per 100,000 people. Median age of diagnosis is 64 years, and it
is more common in men as compared to women. Survival is poor with approximately
40% survival in the first-year post diagnosis and 17% in the second year. GBM
symptoms might different when it locates different locations of brain, but usually

includes constant headaches, seizures, vomiting, changes in mood or personality, etc.
The prognosis of GBM remains poor, despite with the development of advanced
new surgical techniques combined with radiotherapy and chemotherapy 4. The median

length of survival after a diagnosis is 15-18 months 2. The current mainstay of treatment
1

for GBM patients is surgery, followed by radiation therapy with temozolomide (TMZ, an
oral alkylating chemotherapy medicine) 5. However, GBM usually recurs within couple

months after the surgery. Identification of new molecular targets to develop more
effective drugs for GBM treatment is very urgent, the current mainstay treatment protocol

caused the low median survival rate for GBM patients.

1.2 Current strategies for GBM treatment
A brief summary of existing treatment options for GBM is shown in Figure 1. The

current standard treatment for GBM is surgery. The primary goal of surgery is to remove
as much of the tumor as possible without injuring the surrounding normal brain tissue
needed for normal neurological function 6. However, glioblastomas are surrounded by a

zone of migrating tumor cells that invade surrounding tissues, making it nearly

impossible to remove the entire tumor 7. Surgery provides the ability to reduce the

amount of solid tumor tissue within the brain, removing those cells in the center of the
tumor that may be resistant to radiation or chemotherapy. Overall, surgery prolongs the
lives of some patients and improves the quality of remaining life but does not cure the
patients. Chemotherapy was first introduced at 1970s, Carmustine (BCNU) was the first

chemotherapy drug reported which could cross blood brain barrier (BBB) and kill GBM
cells directly 8. In 1979, Salazar et al employed radiation therapy in GBM treatment,
which proved to be effective 9. Targeting therapy was introduced in 2008. Avastin
targeted the blood vessels by inhibiting angiogenesis in order to block the nutrition

supply to brain tumor to kill the cancer. Currently, the mainstay of treatment of
glioblastoma is surgery, followed by radiation and chemotherapy. Radiation therapy uses

high-energy beams, such as X - rays to kill cancer cell. For people who cannot undergo
2

surgery, radiation therapy is used as the primary treatment. In some cases, thin, circular

wafers containing chemotherapy medicine may be placed in the brain during surgery. The
wafers dissolve slowly, releasing the medicine which kills the cancer cells. Currently,

TMZ was introduced in 1999, still the first line to treat the glioblastoma. Tumor treating
fields (TTFields) is a new non-invasive strategy that involves provision of low intensity

(1-2 V/cm) and intermediate frequency (100 kHz to 1 MHz) electric fields to the tumor.
TTFields interfere with mitotic processes within rapidly dividing GBM cells, causing cell

death 10. TTfields are applied by placing electrodes on the shaved skull, does cause mild
dermatitis and local skin irritation are commonly reported side effects 11. TTfields have

been approved for both newly diagnosed and recurrent GBM in 2011 and 2015,

respectively 7,12. Seviteronel, an antiandrogen drug, was considered to be a promising
anti-androgen receptor expressed GBM agent 13. Unfortunately, seviteronel treatment of
GBM patients was terminated after phase II trials in 2021 14.

Figure 1. The timeline of GBM therapy.

1.3 Current GBM treatment challenges
There are three main challenges involved in the treatment of GBM. These are

heterogeneity within the same tumor which facilitates the selection of resistant
subpopulations, the fortified location of tumor which hinders delivery of therapeutics, as

3

well as the induction of strong local immunosuppression that promotes immune evasion
and restricts the efficacy of emerging immunotherapies.

First, the proliferative property of GBM cells cause the fast resistance development
and eventual relapse 15,16. Studies proved that GBMs have specific local tumor

microenvironments (TME) that determine the ability of a specific tumor region to invade
surrounding tissues and resist conventional radiotherapy and chemotherapy 17. Second,

GBM induced immunosuppression may further contribute to treatment failure. Multiple

pathways have been reported to contribute to immunosuppression, including the
recruitment of tumor associated macrophages which promote immune evasion, tumor

growth, invasion and angiogenesis 18.
Second, in brain tumors, delivery and penetration of therapeutic agents is further
restricted by the presence of the blood-brain barrier (BBB). The BBB is a highly

complicated and structured neurovascular entity responsible for controlling neural
homeostasis and penetration of substances into the brain. The BBB includes cerebral
endothelial cells, pericytes, astrocytes, microglial and smooth muscle cells 19. The BBB

has unique structure, which including tight junctions and absence of fenestrations lead to
an impenetrable barrier 20. Therefore, only selective substances such as small (< 500 Da)

molecules can passively diffuse across the BBB 21. It has been reported that almost all
large molecular weight drugs and about 98% of small active pharmaceutical ingredients
(API) are unable to permeate the BBB

22,23.

The BBB plays an important role in

protecting the brain from toxins and other harmful substances, but this is a double-edged

sword as it also impedes the delivery of therapies to the tumor 21.

4

Third, drug resistant is common in the treatment of GBMs. The oral chemotherapy
drug TMZ is often used during and after surgery and radiation therapy. Clinical evidence
showed that TMZ treatment can extend patient’s post-operative survival, but most cases
eventually demonstrate resistance to TMZ. O6-methylguanine produced by TMZ miss

pairs with thymine during DNA replication, alerting DNA mismatch repair. Mismatch
repair recognizes the mis paired thymine on the daughter strand and excises it. However,
O6-methylguanine persists in the template strand, so cycles of thymine reinsertion and

excision result in DNA strand breaks, causing the cell death. However, O6methylguanine- methyltransferase repairs the main cytotoxic lesion, as O6-methylguanine,

generated by TMZ, can be the main mechanism of the drug resistance.

1.4 Androgen receptor: a potential therapeutic target for GBM
A statistical data indicated that the incidence of glioma in men is higher than that

in women 24. This indicates that glioblastoma is sex related. Sex hormone or its relevant
signal pathway might be involved in moderating glioblastoma occur in our human body.

It is well known that the androgen receptor (AR) is a ligand, which is an activated nuclear
receptor that plays a critical role in normal prostate physiology, as well as in the

development and progression of prostate cancer 25. The ligand - induced conformational
change facilitates the formation of AR homodimer complexes that can then bind to
androgen response elements in the promoter regions of targets. Recently, studies showed

that AR has high expression in glioblastoma cells, while having minimum expression in
normal tissue 26. Moreover, downregulating AR gene level can induce glioblastoma cell

death in vitro 27. This research indicated that AR play an important role in regulating

GBM proliferation. It is well known that AR is activated by binding its ligand, androgen.

5

Thus, AR antagonist competes with androgen binding to AR to inhibit AR signaling,
making it a potential drug to treat GBM. However, mutant AR was detected in
glioblastoma, even targeting AR still promising

27.

This AR variant, AR-V7, which lacks

the ligand-binding domain, which indicating, AR antagonist will not be effective in

downregulating AR-V7. This might explain that why Seviteronel failed in the clinical
trials phase II for the treatment of GBM.

1.5 HSP27 and AR relationship

Heat shock 27 kDa protein (HSP27) plays an important role in the folding,

activation and regulation of transcriptional activity of many steroid receptors such as AR
28. The overexpression of HSP27 is vital to stabilize AR. AR is in the cytoplasm in the
absence of ligand, forming a complex with chaperones and co-chaperones like heat shock

proteins. Upon ligand binding, AR undergoes conformational changes and translocases to
the nucleus, where it binds to the androgen response elements (AREs), which activate the

expression of AR target genes to induce cell proliferation, differentiation, and survival

(Figure 2).
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Figure 2. Schema demonstrating AR and HSP27 interactions: Testosterone (T) was
reduced by 5-α reductase, produced dihydrotestosterone (DHT). DHT binding to AR
recruit HSP27 escort the dimer complex translocate into nucleus, triggering ARE gene
induce cell proliferation. However, with the presence of OGX-427, a HSP27 antisense
oligonucleotides (ASO), could interrupt HSP27, induce AR degradation via ubiquitin
proteasomal pathway.

1.6 Targeting HSP27: a novel approach for the treatment of GBMs
Recently, many researches indicate that targeting HSP27 can induce AR

degradation in prostate cancer 27-28. Zoubeidi et al introduce HSP27 antisense
oligonucleotides (ASO), OGX-427 to disrupt HSP27 in prostate cancer (Figure 2). The
effects of OGX-427 on AR degradation was verified in vitro and in vivo. In prostate
cancer, AR is critically important. OGX-427 induces HSP27 level decrease, thus,

destabilizes AR and induce its ubiquitination and degradation. However, GBM is unique
7

type of cancer, which is different to prostate cancer due to the presence of BBB. ASO and
siRNA HSP27 inhibitors are not applicable in GBM because of the poor BBB penetration

of their biological agents. It is impossible to study the transient dynamic characteristics

between HSP27 and Ars with HSP27 gene silencing techniques because they do not
directly interfere with Ars and HSP27 inhibitors without the administration difficulties

and high potential to pass the BBB would demonstrate promise for great clinical
outcomes in GBM treatment.

In the following chapters, my research will demonstrate that targeting HSP27 has
the significance of inhibiting GBM growth in vitro and in vivo. In our previous study,
compound I is a HSP27 inhibitor that significantly induces AR degradation in GBM cells

via the proteasomal pathway. It selectively inhibits AR overexpressed GBM cells growth
with IC50 values around 5 nM. Compound I also significantly inhibit in vivo GBM
xenograft at 20 mg/kg and does not cause toxicity to mice up to 80 mg/kg 29. These

results indicate that targeting HSP27 to induce AR degradation in GBM is a promising
and novel treatment approach.

8

CHAPTER II

STATEMENT OF THE RESEARCH AND SPECIFIC AIMS

2.1 The Research Problem

Glioblastoma (GBM), referred to as a grade IV astrocytoma, is the most common
and malignant brain cancer and is considered the most aggressive malignant brain cancer

in adults. It invades the nearby brain tissue, but generally does not spread to distant
organs. GBM can develop in the rain from the lower grade astrocytoma. In adults, GBM

occurs most often in the cerebral hemispheres, especially in the frontal and temporal
lobes of the brain. GBM is a devastating brain cancer, and the median overall survival is

only 20.9 months. The incidence of GBM is 50% greater in men than in women. GBM

has an incidence of 3.21 per 100,000 people. Median age of diagnosis is 64 years, and it
is more common in men as compared to women. The current mainstay of treatment of

GBM is surgery, followed by radiation and chemotherapy. The primary aim of surgery is
to remove as much of tumor as possible without damaging the surrounding normal brain

tissue. However, GBM invades surrounding tissues, making it impossible to ever remove
the tumor entirely. After surgery, the oral chemotherapy drug temozolomide (TMZ) is

often used during and after radiation therapy. Clinical evidence showed that TMZ

9

treatment can extend patient’s post-operative survive but most cases eventually

demonstrate resistance to TMZ. Therefore, identification of new molecular targets to
develop more effective drugs for GBM treatment is very urgent.

The Statistical data showed that the incidence of GBM in men is about 1.6 folds
higher in men than in women. Furthermore, it is reported that androgen and the androgen
receptor (AR) correlated pathway play important in GBM proliferation. Thus, targeting

AR could a potential approach in GBM treatment. However, mutant AR commonly

occurred in GBM, which makes the antiandrogen agents less effective. Heat shock 27
kDa protein (HSP27) is a well-documented chaperone protein to stabilize AR. Inhibition
of HSP27 results in AR degradation regardless of the mutation status of AR, which

indicates that HSP27 could be a potential target to abolish AR in GBM.

2.2 Specific Aims
1. To identify small molecules HSP27 inhibitors could inhibit androgen receptor and
suppress glioblastoma.
2. To verify the small molecule identified could cross blood-brain barrier.

3. To synthesize new derivatives by structural modification to the compound I,
identified HSP27 inhibitor. To determine the anti-glioblastoma activity in vitro
and in vivo of the new compounds.
4. To verify the toxicity in vivo and the permeability of blood brain barrier of the

new candidates.

10

CHAPTER III

SMALL MOLECULE HSP27 INHIBITOR ABOLISHES ANDROGEN
RECEPTOR IN GLIOBLASTOMA

3.1. Introduction

GBM is the most common and malignant tumor of the brain. The prognosis of
GBM patients remains poor, even with the progress in the development of new surgical
techniques and the standard chemotherapy of TMZ combined with radiotherapy 30-32.
TMZ is an alkylating agent that is considered the most efficient chemo drug in GBM

therapy due to its good capability to pass BBB. However, de novo and acquired resistance
to TMZ treatment are very common in GBM patients, resulting in a poor outcome 32.

Identification of new molecular targets to develop more effective drugs for GBM

treatment is very urgent. On the other hand, the incidence of GBM in men is higher than
that in women, which also is associated with men experiencing poorer outcome 33,34.
Moreover, there are well reported cellular, molecular and imaging alterations that

11

underline these sex differences 34,35. These findings suggest that involvement in sex

hormones could play a role in GBM development.7 To elucidate this sex disparity, studies
found that AR is overexpressed in GBM and androgens contribute to the GBM tumor
progression 27,36-39. The overexpression of AR and the role of androgen in GBM are
consistent to the gender-related discrepancy of this disease. Therefore, targeting AR
becomes a novel approach in GBM and an AR inhibitor Seviteronel has been investigated

in clinical trials for AR overexpressed GBM patients 40. Unfortunately, AR mutation
happens in 30% of the AR overexpressed GBM patients 27, which very likely limits the

effectiveness of AR targeting agents in the treatment of GBM. It is critical to find
alternative approach to diminish AR activity in GBM.

In fact, AR is correlated to a small chaperone protein HSP27 that exists in multiple

oligomeric states within the cells. Overexpression of HSP27 increase the stability of its
client proteins and protects cancer cells from various treatment induced cell death 41. The
critical connection between HSP27 and AR is AR is a well-documented HSP27 client

protein 28,41. HSP27 is responsible for AR stability and seems a good direct target for
HSP27-AR pathway in GBM. HSP27 functions through an ATP-independent mechanism
and therefore could not be inhibited with geldanamycin derivatives that target the ATP-

binding site of chaperone proteins 42-44. Strategies to inhibit HSP27 at the mRNA level
are alternative approaches to suppress the protein activity 41,45. Gene silencing strategies

using short interfering RNA (siRNA) and antisense oligonucleotides (ASO) to disrupt
HSP27 have been investigated and AR level was consequently reduced 28,41,46.

Unfortunately, GBM is different from other cancer types due to the BBB protection. ASO
and siRNA HSP27 inhibitors are not applicable in GBM due to the poor BBB penetration
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of these biological agents. In addition, it is impossible to study the transient dynamic

characteristics between HSP27 and AR with HSP27 gene silence techniques, since they
don’t directly interfere with AR and HSP27 at protein level. Small molecule HSP27

inhibitors without the administration difficulties and high potential to pass BBB would

demonstrate promise for great clinical outcomes in GBM treatment. They can also be
used to investigate the transient changes of HSP27-AR interaction following rapid

HSP27 inhibition.

In our previous study, we developed dual HSP27 and tubulin inhibitors based on
nimesulide (COX-2 inhibitor) as a lead compound 47. The derivatives showed both
inhibitory activity to HSP27 chaperone function and tubulin polymerization 48. Some of
the compounds showed great potency against cancer cell growth with IC50s at the low

nanomoles 48,49. Due to the HSP27 targeting effect, we hypothesize that the small
molecules could affect the stability and function of AR, which could make these
compounds potential candidates to target AR overexpressed GBM 48,49. In the present

study, we systematically investigated a promising lead compound for the in vitro and in
vivo anti-glioblastoma activity. The targeting effect of the compound to AR stability via

HSP27 inhibiting was confirmed. The compound showed selectivity to AR overexpressed
GBM cells and also induced AR degradation in both in vitro and in vivo GBM models.

Via the toxicity study, we identified the structure moieties that are critical to the low
toxicity profile and provided a new direction for future structural modification. Our

results indicate that the HSP27 inhibitor has great potential to be a group of novel agents
for the treatment of AR overexpressed GBM.
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3.2. Materials and methods

3.2.1. Reagents

Compounds I-IV were prepared by our own lab. Prostaglandin E2 ELISA kit
(Cayman Chemical Company, 514010). Thiazolyl Blue tetrazolium bromide, 98% (Alfa

Aesar, P31B064). Tubulin (> 99% pure) was isolated from bovine brain (Cytoskeleton,

TL238). GTP (Cytoskeleton, BST06). Tubulin glycerol buffer (Cytoskeleton, BST05-

001). Tubulin general buffer (Cytoskeleton, BST01-010). Insulin (Sigma Aldrich,
91077C). α-Crystallin (Sigma Aldrich, C4163). Dithiothreitol (DTT) (Amresco, EC#

222-468-7). MG132 (Sigma Aldrich, C2211). DMEM (Cleveland Clinic media
laboratory, 11-500p). RPMI 1640 (Cleveland Clinic, 10-500p). FBS (Atlanta Biologicals,

S11150). Pen/Strep solution (Cleveland Clinic, 725-100p). Anti-β-actin antibody (Cell
Signaling Technology, 4967S). RiboZol Reagent (VWR, 97064-952). DNase I (Promega,

M6101).

ImProm-IITM

Reverse

Transcription

System

(Promega,

A3800).

4%

paraformaldehyde (VWR, J61899-AK). Bovine serum albumin (Millipore Sigma, 2905-

OP). DAPI (VWR, 95059-474). Anti-HSP27 antibody (Cell Signaling Technology,

2402S). Anti-Androgen Receptor antibody (Cell Signaling Technology, 5153S). AntiAR-V7 antibody (Cell Signaling Technology, 68492S). Anti-Rabbit IgG (Cell Signaling

Technology, 7074S). Anti-Rabbit Alexa Fluor 488 secondary antibody (Thermo

Scientific, A-21206). Anti-Mouse Alexa Fluor 594 secondary antibody (Thermo
Scientific, SA5-10168). Non-Fat dry milk (Rockland, B51-0500). Chemiluminescent
Substrate (Thermo Scientific, 34577). All the other chemicals are analytical grade.
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3.2.2. Cell culture

T98G, A172, U87 and U251 cells were from ATCC. The cells were maintained in

RPMI1640 or DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL
penicillin and 100 mg/mL streptomycin in a humidified incubator with 5% CO2 at 37 °C.

3.2.3. Compounds I-IV

The synthesis of the four compounds has been published in our previous

studies.21,22 All the final compounds exhibited purities above 97%. The chromatographic
separation was performed on a C18 column (2.0 mm × 150 mm, 5 μm) from Phenomenex

(Torrance, CA). Two mobile phases (H2O/CH3OH; H2O/CH3CN) were employed for

isocratic elution with a flow rate of 0.2 mL/min. The injection volume was 20 μL and the

UV detector was set up at 256 and 290 nm.

3.2.4. Cell viability analysis

MTT assay was used to evaluate the effect of dual HSP27 and tubulin inhibitors on
the growth of T98G, A172, U87 and U251 cells in eight replications. 3000 cells per well
were seeded with RPMI1640 or DMEM in 96-well flat-bottomed plates for 24 h and were

then exposed to various concentrations of test compounds dissolved into DMSO (highest

final concentration 0.1%) in the medium for 48 h. controls received DMSO at a same
concentration as that in highest does drug-treated cells. Cells were incubated in 100 μL 1
mg/mL of MTT reagent diluted in fresh media at 37 °C for 2 h. Supernatants were
removed from the wells, and the precipitated MTT dye was dissolved in 200 μl/well
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DMSO. Absorbance at 570 nm was determined on a SpectraMax Plus 384

spectrophotometer (Molecular Devices).

3.2.5. Experimental animals

Male CD-1 mice and nude mice were purchased from Taconic lab. Mice were
housed in Plexiglas cages, kept on a 12/12 -h light-dark cycle, and received food and
water ad libitum in a temperature- and humidity- controlled environment. All the
experimental procedures involving animals were performed in accordance with the guide

for the Care and Use of The Cleveland State University (CSU) Institutional Animal Care
and Use Committee (IACUC).

3.2.6. Maximum Tolerated Dose (MTD) study

20 CD-1 mice were randomly divided into five groups. Mice were injected with

vehicle (DMSO) or compounds I-IV (80 mg/kg in PBS) by intraperitoneal injection (IP)
three times weekly. Mice would be euthanized once the toxicity (e.g., dehydration,

lethargy, disorientation, hunched posture and ruffled coat) was observed. Body weights
were determined at the start dosing day and the end dosing day. Non-fasted blood

samples were collected from the heart immediately for hematology analysis after the

euthanizing. Hematology analysis was performed with a hematology analyzer—Element
HT5 (Heska Corporation, USA).

16

3.2.7. Western blotting

Cells were cultured in 6-well culture plates and incubated with DMSO or inhibitors
and then lysed with RIPA (Thermo Scientific, Prod# 89900) supplemented with a

protease inhibitor cocktail (Thermo Scientific, Prod# 1861278). After incubating the cells
on ice for 10 min, lysates were collected into a 1.5 mL centrifuge tube, then, the

supernatant would be collected after centrifuged at 10,000 g for 10 min. Protein
concentrations were determined by the Bradford Protein Assay kit (Bio-Rad). Fifty
micrograms of total protein lysate for each sample were boiled with 1x loading buffer for
10 min. Samples were then separated on a 10% SDS-polyacrylamide gel and transferred
to polyvinylidene fluoride (PVDF) membrane (Bio-Rad). The membrane was blocked for

2 h with 5% non-fat milk in 1x TBS-T (150 mM NaCl, 10 mM Tris, pH7.4, 0.1% Tween

20) at room temperature and then incubated with primary antibody at 4°C overnight.
After the membrane was incubated with the primary antibody and washed three times
with 1x TBS-T for 10 min each wash, it was incubated with the secondary antibody for 60

min at room temperature. The membrane was washed three times again for 10 min each
time with 1x TBS-T. Eventually, the membranes were incubated with SuperSignal West

Pico Chemiluminescent Substrate (Pierce) according to the protocol of the manufacturer.

3.2.8. Tubulin polymerization assay

A mixture of 100 μL of microtubule-associated protein-rich tubulin (2 mg/mL,
Bovine brain, Cytoskeleton) in buffer containing 80 mM PIPES (pH 6.9), 2 mM MgCl2,

0.5 mM EGTA, and 5% glycerol was mixed with DMSO (as control) or various
concentrations of compound I in DMSO and incubated at 37 °C. Then 1 μL of 100 mM
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GTP was added to the mixture to initiate the tubulin polymerization and the absorbance at
340 nm was monitored every single minute continuously for 45 min using Molecular

Devices SpectraMax Microplate reader.

3.2.9. HSP27 chaperone activity assay

24 μL 1 mg/mL insulin stock solution was added to the single well of 384 well

plate, 3 μL 5 mg/mL α -crystallin (a segment of HSP27 responsible for the chaperone

function of HSP27), 71 μL PBS with 10 μM compound I dissolved inside were added as
well. The mixture was thoroughly mixed and incubated at 37 °C for 5 min, then 2 μL of 1

M DTT in water was added to initiate the insulin aggregation. The mixture of insulin in
the absence or presence of α-crystallin with 0.1% DMSO was used as control. The

absorbance at 400 nm was monitored every three minutes continuously for 2 h using
Molecular Devices SpectraMax Microplate reader.

3.2.10. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis

T98G and U87 cells were seeded at a density of 2×105 cells per well in a 6-well

plate. Leave cells in incubator overnight to adhere and treat with compound I at 25 nM
for 12 h. Total RNA was isolated via using RiboZol reagent according to the

manufacturer's

instructions.

RNA

yield

and

purity

were

determined

spectrophotometrically at 260-280 nm and the integrity of RNA verified by
electrophoresis through denaturing agarose gels stained with ethidium bromide. To
remove DNA contamination from the RNA samples, 10 μg of total RNA was incubated

with 10 units of RNase-free DNase I at 37°C for 30 min, followed by Phenol/Chloroform
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Extraction and Ethanol Precipitation. Then, 1 μg of DNase I treated RNA was reverse
transcribed into cDNA using the ImProm-IITM Reverse Transcription System according
to the protocols. The iTaq Universal Sybr Green Super mix was obtained from Bio Rad

and used for setting up real-time PCR reactions. And the specific primers for real-time
PCR were designed using the Primer Express software (v3.0; Applied Biosystems). The

relative levels of each gene mRNA transcripts to 18S were determined. The primer
sequences

for

AR,

PSA,

NKX3.1

and

18S

were

as

follows:

AR:

GGCCAGGAAAGCGACTTCA (forward); CCCATTTCGCTTTTGACACA (reverse).

TGTGCTTCAAGGTATCACGTCAT

PSA:

CTTGATCCACTTCCGGTAATGC

(reverse).

(forward);

NKX3.1:

CTTGGAGAAGCACTCCTCTTG (forward); CGCAGTACAGGTATGGGT AGTA
(reverse).

18S:

TCGGAACTGAGGCCATGATT

(forward);

CTTTCGCTCTGGTCCGTCTT (reverse). The comparative cycle of the threshold

fluorescence method was applied, and the relative transcript amount of the target gene

was normalized to that of 18S using the 2-AACt method. Three replicates were performed
per cDNA sample.

3.2.11. Immunofluorescence assay

T98G and U87 Cells were seeded in 6-well plates. Cover slips were placed into the
wells and the cells could attach naturally. After 24 h, cells were treated with compound I

at 100 nM, DHT at 10nM or combination for 12 h. Then, cells were fixed with 4%
paraformaldehyde for 20 min, permeabilized with 0.1% Triton X-100 for 10 min, blocked
with 1% bovine serum albumin for 30 min. Several washing steps with TBST-BSA (5%)
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occurred in between fixation, permeabilization and blocking. Then, incubation with the
AR and HSP27 primary antibodies for 1 h. Followed by washing with TBST-BSA (5%)
then fluorescein-labeled secondary antibodies for 1 h DAPI was incubated for 10 min to

stain the nucleus. Images were visualized and analyzed using GE Launches

DeltaVision™ Ultra Microscopy System.

3.2.12. Computational study

Docking studies were done using the molecular modeling program MOE version

2019.0102 (Chemical Computing Group). Each protein target, HSP27 (6DV5.pdb) and
tubulin (1SA0.pdb) were prepared for docking using the QuickPrep function, which adds

hydrogens, and optimizes the hydrogen orientation for pH 7.4; additionally, any missing
loops or crystallographic steric classes were fixed. The binding pocket of HSP27 was

identified from the literature,50 and for tubulin, the colchicine binding site was chosen as
per our previous work.48 For the docking study, an induced-fit docking model was used,

since compound binding to proteins may induce changes in the amino acid orientation to

allow for optimal binding between ligand and protein. For each protein, 10 binding poses
were generated, and visually inspected for optimal binding interaction.

3.2.13. Cyclooxygenase-2 (COX-2) inhibition assay

From our previous research, all four inhibitors in this paper are derivative from
COX-2 inhibitor nimesulide 47, and their COX-2 inhibition activity still remain to be

determined. Prostaglandin E2 production is an indicator of COX-2 activity since COX-2
could catalyzes the conversion of substrate arachidonic acid to prostaglandins 46. In this
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study, compound I (10 nM) were treated in U87 cells for 12 h, and nimesulide (10 μM)
was the positive control. After the treatment, the cell media was taken to determine
prostaglandin E2 content via prostaglandin E2 ELISA kit (Cayman Chemical, USA).

3.2.14. In vivo xenograft study

U87 cells were re-suspended in sterile PBS (100 μL) and injected (5×106

cells/injection) subcutaneously at the left and right flank of a male nude mouse (5-6
weeks, n = 4/group, 2 tumors per mouse and 8 tumors per group). Tumors and body

weight were monitored with Vernier calipers three times weekly, and tumor volume was

calculated by the following formula: V= 2/3 d1×d22, where d1 is the larger diameter and
d2 is the smaller diameter. When the tumor volume reached approximately 50 mm3, mice

were injected with vehicle (DMSO) or compound I (20 mg/kg in PBS) by IP or oral

administration three times weekly for 14 days, and the tumor size were monitored and

measured at the same time. In the end, mice were euthanized by exposure to excess CO2
and the tumors were removed, weighted. And every two tumors from every single one

mouse was mixed and homogenized with RIPA buffer (Protein inhibitors and PMSF were

added) to prepare the tumor lysates after tumor were weighted.

3.2.15. Statistical analysis

Statistical and graphical information was determined using GraphPad Prism
software (GraphPad Software Incorporated) and Microsoft Excel (Microsoft Corporation).
Gray values from western blot were determined via Quantity One Software (Bio-Rad).

The determination of IC50s was performed using nonlinear regression analysis.
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Statistically significant differences were calculated with the two-tailed unpaired Student’s

/-test andp values reported at 95% confidence intervals.

3.3. Results and discussion

3.3.1. AR and mutated AR are detected in GBM cell lines

It has been demonstrated that AR is highly expressed in some of the GBM
patients and contributes to higher disease accidents in men than in women 27,35,36. Due to
the high mutation of AR in GBM, AR antagonists could not be very effective for the

treatment of GBM in this regard 27,37. Abolishing the AR protein in glioblastoma cells has
more advantages, because both wild type and mutated AR could be both eliminated by
this strategy 27,37-40. Therefore, we initiated the novel approach to induce AR degradation
via inhibition of HSP27 in glioblastoma cells, because AR is a well-documented client

protein of HSP27, and its stability is dependent on HSP27.
Multiple glioblastoma cell lines are used in our study for the potential drug
candidate mechanism and efficacy evaluation. To examine the AR and HSP27 status in

these glioblastoma cells, we used western blotting assay to check the protein levels in the

four cell lines including, T98G, U251, A172 and U87 (Figure 3). Highest AR expression

in T98G cells is observed, and U87 shows weaker expression, whereas U251 and A172
do not show clear AR expression compared to other two cell lines. To further explore the

mutated AR (AR-V7, N terminus truncated AR with a molecular weight of 87 kDa) in
these cells, we used antibody specific for mutated AR and found that only T98G cells

express the mutated version of AR. The other three cell lines do not show clear protein

bands. HSP27 is observed in three cell lines with the higher levels in T98G and A172
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cells, whereas U251 cells do not express detectable HSP27. It seems that when AR and

HSP27 are co-expressed in the cells, higher HSP27 could contribute to higher AR, as

indicated by T98G cells. When AR is not expressed in the cells, higher HSP27 may

contribute to the stability of its other client proteins, which is not our focus of the study.
T98G and U87 cells both show detectable HSP27 and AR, and they could be good

models for the investigation if targeting HSP27 could induce AR degradation.

Figure 3. AR, mutated AR (AR-V7) and HSP27 expression in four GBM cell lines. The
proteins were analyzed by western blot with specific antibodies, and the results are the
representative images and quantification. Data are expressed as Means ± SD (n=3).

3.3.2. Four drug candidates showed promising selectivity and activity inhibiting the
growth of AR overexpressed GBM cells

To identify the most promising compounds targeting GBM, we investigated the in

vitro activity of the four nimesulide analogs developed from our previous studies (Figure
4) 48,49. These compounds were discovered as dual HSP27 and tubulin inhibitors and

showed inhibitory activity to the in vitro chaperone activity of HSP27. The HSP27
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inhibition of the compound trigger our interest to investigate if the compound could

target the AR function of the GBM cells. First, we examined if the compound could
inhibit the growth of the GBM cells with cell proliferation assay. The IC50s of the

compounds against the proliferation of the four GBM cell lines were determined with

multiple doses, and the results are exhibited in Table 1. All the IC50s are less than 20 nM,

indicating the great potency of the compounds in the in vitro cell proliferation assay.

Together, all four compounds showed relatively better potency to T98G cells that express
higher level of AR expression, suggesting that the selectivity of the compounds is

correlated to the AR expression in the cells. Overall, compounds with ethyl sulfonamide
moiety are less active than methyl sulfonamide compounds, suggesting this domain may

fit into a small pocket of the molecular target.

Figure 4. The chemical structures of compounds I-IV.
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Table 1. The growth inhibitory effects of the four compounds in GBM cells.
Compounds

IC50s (nM)

T98G

U251

A172

U87

I

2.01±0.64

4.00±1.20

6.24±1.06

4.78±1.62

II

4.87±2.04

6.39±1.94

11.96±2.77

6.74±2.73

III

1.85±0.81

1.57±0.33

3.13±0.78

3.05±1.16

IV

5.71±1.99

6.97±1.08

8.21±2.26

7.83±3.81

3.3.3. N-methyl group is the key moiety of the compounds causing in vivo toxicity

To identify the most promising drug candidate from the four compounds for further

investigation, we used in vivo toxicity as a criterion. Mice were exposed with the four
compounds at 80 mg/kg per day to evaluate the toxicity. For compounds III and IV, mice

started to show dehydration and reduced food consumption after 5 days and 7 days,
respectively, and were euthanized accordingly. For compounds I and II, mice did not
show any syndromes of toxicity such as acute pain or distress, weight loss even at day 10.

All the rest of the mice were euthanized at day 10. To quantitively determine the in vivo
toxicity, the weight of the mice weight was analyzed. Compounds III and IV (N-methyl

group) significantly (p < 0.05) decreased the body weight of mice by the 5th and 7th day
of exposure, while compounds I and II (N-hydrogen group) had no weight changing

compared to control group (Figure 5). And the hematology results of all the mice are
listed in Table 2. There is no significant change for the profile of the blood even for
compounds III and IV that showed toxicity to the mice. The results reveal that
compounds I and II without the N-methyl group are less toxic to the animals compared to
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the compounds with the N-methyl group, suggesting that the methyl group seems play a

critical role for this toxicity. Considering the in vitro selectivity, activity and in vivo
toxicity, compound I has more potential to be a better drug candidate. Therefore, we

focused on the molecular mechanism investigation of compound I in AR overexpressed
GBM cells.

Figure 5. Effect of compounds I-IV on body weight with the intraperitoneal injection at
dose of 80 mg/kg. CD-1 mice were exposure to both compounds I and II, III and IV for
10, 5 and 7 days, respectively. Body weight were measured at the beginning and the end
of the experiment. Data are expressed as Means ± SD (n=4). *p < 0.05, **p < 0.01
compared to DMSO group with unpaired t test.
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Table 2. Comparative hematology (Mean ± SD) between different groups.
Group

Parameters

Reference

Control

C1

C2

C3

C4

Range

WBC
(10^3∕μL)

2.15±0.63

8.71±2.71

14.33±3.3

2.72±1.4

7.30±0.96

0.80-10.6

Neu
(10^3∕μL)

0.27±0.30

4.07±2.09

8.09±2.62

0.86±0.6

4.32±1.75

0.23-3.60

Lym
(10^3∕μL)

1.64±0.41

3.95±0.56

5.20±0.57

1.10±0.6

1.87±0.59

0.60-8.90

Mon
(10^3∕μL)

0.10±0.05

0.22±0.05

0.61±0.15

0.16±0.1

0.65±0.04

0.04-1.40

Eos
(10^3∕μL)

0.12±0.12

0.36±0.10

0.28±0.03

0.46±0.1

0.23±0.06

0.00-0.51

Bas
(10^3∕μL)

0.02±0.02

0.12±0.03

0.16±0.06

0.14±0.1

0.24±0.19

0.00-0.12

Neu (%)

12.43±3.34

44.65±9.19

55.90±5.1

29.67±7

58.00±16

6.50-50.0

Lym (%)

76.75±6.2

47.05±8.16

36.80±4.6

40.13±2

26.35±11

40.0-92.0

Mon (%)

4.75±1.44

2.55±0.33

4.20±0.14

6.17±1.0

8.95±0.64

0.90-18.0

Eos (%)

5.18±3.75

4.30±1.52

2.00±0.71

19.30±11

3.25±1.20

0.00-7.50

Bas (%)

0.90±0.70

1.45±0.25

1.10±0.14

4.73±1.7

3.45±3.04

0.00-1.50

RBC
(10^6∕μL)

7.24±2.08

7.64±0.64

7.59±1.21

9.41±2.1

8.33±0.13

6.80-12.00

HGB (g∕dL)

13.10±3.13

13.96±0.60

13.50±2.1

17.47±3

15.40±0.3

10.5-19.0

HCT (%)

36.48±10.6

39.65±2.53

38.80±5.5

47.20±11

40.85±1.2

37.2-58.0

MCV (fL)

50.43±0.90

51.95±1.59

51.2±0.85

50.00±2

49.05±0.6

42.6-55.6

MCH (pg)

18.38±1.45

18.28±0.90

17.85±0.1

18.63±0

18.50±0.0

13.0-19.8

MCHC
(g∕dL)

36.45±2.61

35.18±1.07

34.85±0.5

37.30±2

37.70±0.6

26.0-37.9

RDW-CV
(%)

12.58±0.46

13.78±0.37

13.40±0.7

17.50±1

14.40±0.1

11.1-21.1

PLT
(10^3∕μL)

180.3±191

983.8±392

977.5±419

551±101

1075±585

565-1849

MPV (fL)

5.70±0.22

5.95±0.24

6.15±0.07

6.47±0.3

7.40±0.28

3.6-6.8

*Reference ranges obtained from Heska hematology analyzer based on the age, sex of species
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3.3.4. Compound I inhibits chaperone activity of HSP27

This group of compounds were previous identified to bind to both HSP27 and
tubulin 47. Therefore, we determined if compound I affect the chaperone activity of

HSP27. Our hypothesis is that the compound has the potential to downregulate AR via
HSP27 inhibition. It is well documented that HSP27 plays a vital role in the prevention of

cell apoptosis and effectively prevents the aggregation or degradation of its client
proteins

50.

The cellular protective functions of HSP27 in the apoptotic pathway are

regulated by its chaperone activity, and this activity contributes to the protection of cells
from stress stimuli

51.

To examine the in vitro chaperone activity, insulin is often used as

a model substrate protein to mimic the protein aggregation and HSP27 serve as the
chaperone to prevent the aggregation 52,53. In this study, DTT could denature insulin,

which induces insulin B chain to aggregate. We used alpha crystallin that is the
chaperone function domain of HSP27 to perform the chaperone assay 54. In the presence

of the chaperone protein, the aggregation of insulin can be suppressed due to the

formation of stable complexes between the chaperone and the unfolded B chain 55.
Aggregated insulin could be examined via the absorbance at 400 nm. The capability of
compound I to modulate the in vitro chaperone activity of HSP27 was evaluated by

monitoring the DTT-induced insulin aggregation in the presence of alpha crystallin, with
or without compound I. As shown in Figure 6, alpha crystallin exhibits significant
potency against DTT-induced insulin aggregation. Compound I does not interfere with

DTT-induced insulin aggregation directly.

When compound I and α-crystallin are

combined, the chaperone function of α-crystallin is reduced. Therefore, more insulin

aggregation is observed, and the curve is shifted up compared to the only α-crystallin
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with DTT induced insulin aggregation. The results demonstrate the inhibitory activity of
compound I to the in vitro chaperone function of HSP27.

Figure 6. The inhibition of compound I to HSP27 chaperone function. α-Crystallin lost
the activity to prevent DTT induced insulin aggregation in the presence of compound I.
The kinetics of the DTT-induced insulin aggregation was monitored in the absence of a
chaperone protein, or in the presence of a chaperone protein without or with compound I.
The mixture of insulin and DTT with or without other components in the assay buffer
was incubated for 45min at 37 °C and the absorbance at 400 nm was measured. The
compound at this concentration or below did not interfere with DTT and insulin
interaction. The results are representative of three independent experiments and each
curve was measured in triplicate and the mean was used to generate the curve. The
representative one of the three experiments are presented. The statistical analysis was
performed for the end reading of the curve with unpaired t test, p 0.05 with compound I
vs without compound I.
To investigate molecular interaction of compound I with HSP27, we performed a

docking study with the published crystal structure of HSP27 (6DV5.pdb), similar to
previous studies recently published (Figure 7) 55. The crystal structure of HSP27 is a

multimeric system, of which a biologically relevant phosphorylation site is located
between two monomers, with S78 and S82 important for HSP27 phosphorylation 55. We

found that compound I is able to bind to this site, and block S78 by a hydrogen-bond
between the serine residue and the nitrogen from the sulfonamide moiety. This
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interaction is likely contributing to the biological profile of compound I, as preventing
phosphorylation of HSP27 thereby preventing HSP27 interaction with the misfolded
proteins in the cellular environment. The docking result is consistent to the chaperone

inhibition study of compound I.

Figure 7. Binding of compound I with HSP27. A) Multimer HSP27 protein crystal in
ribbon structure (6DV5.pdb. B) Binding pocket between two monomers with compound
shown in space fill; C) Compound I binding to the HSP27 phosphorylation site, showing
SER78 is blocked from phosphorylation; D) 2D ligand interaction diagram of compound
I docked to HSP27 pocket.
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3.3.5. Compound I dose dependently decreases AR and mutated AR protein levels in
GBM cells

AR is a well-studied client protein of HSP27, and inhibition of HSP27 with siRNA

induced AR degradation, which has been reported in prostate cancer 28. Herein we initiate
the HSP27 inhibition strategy with small molecule due to the potential BBB crossing

activity, which is critical for GBM treatment. The results exhibit that compound I could
down regulate AR protein levels in GBM cells dose dependently (Figure 8). Compound I

at 25, 50 and 100 nM all significantly induces degradation of AR compared to control in
two GBM cell lines including T98G and U87. Furthermore, the mutated AR in T98G

cells could be down regulated by compound I dose dependently as well. The results
demonstrate the great superior of the strategy to targeting AR compared to the AR
antagonists, since both wild type and mutated AR could all be abolished by the

compound. The AR downregulation activity of the compound is also consistent to the
selectivity of the compound to AR overexpressed cells in the cell proliferation study

(Table 1). Regardless of the status of AR in glioblastoma cells, wild type or mutated,
small molecule HSP27 inhibitor could all downregulate the AR protein level and inhibit
the cell proliferation. So far, we demonstrate that compound I inhibits HSP27 chaperone

function and down regulates AR in GBM cells. However, whether the two activities are

correlated to each other in GBM just like in prostate cancer still needs to be confirmed.
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Figure 8. Compound I abolishes AR/mutated AR in GBM. AR and AR-V7 expression
was analyzed by western blot after the compound treatment. The experiment was
repeated three times independently and the representative image and quantification are
shown. Data are expressed as Means ± SD (n=3). *p < 0.05, **p < 0.01 compared to
DMSO treatment group by unpaired t test.

3.3.6. MG132 reverses the effect of compound I on AR in both U87 and T98G cells

AR is stabilized by HSP27, and without the protection of HSP27, AR will be
degraded by proteasome, which has been reported in prostate cancer 28,46. We would like

to determine if it is the same case in glioblastoma cells that when HSP27 is inhibited by
compound I, more AR could be degraded by proteasomes. This is based on the

assumption that compound I affects HSP27 activity and thus to accelerate AR
degradation via ubiquitin-proteasome pathway 56. MG132 is a proteasome inhibitor that
can block proteasome mediated protein degradation 57. We use MG132 as a tool to

investigate whether compound I downregulate AR via proteasome pathway in T98G and
U87 cells. The expression level of AR in these cells was determined by western blotting
assay with the treatment of compound I at the absence or presence of MG132, and the

results are shown in Figure 9. Compound I could significantly decrease AR expression at
50 nM and 100 nM in U87 cells (p < 0.01, treatment vs control), whereas with the
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presence of MG132, AR downregulation effect is significantly attenuated (p < 0.05, with
MG132 vs. without MG132). MG132 does not affect AR when used alone. The same

results are observed in T98G cells with wild type of AR and mutated AR as well.
Interestingly, it seems that MG132 does not fully rescued AR protein level in the

combination, particularly in U87 cells. It is possible that the compound could down

regulate AR with other mechanism besides proteasome pathway. In this case, even
proteasome is blocked, AR might be decreased by compound I with some other unknown

pathways. Regardless, the MG132 rescue effect further connects HSP27 with AR in
GBM, and inhibiting HSP27 will lead to AR degradation via proteasome pathway.

Figure 9. The downregulation of AR by compound I is through the proteasome pathway.
AR or mutated AR (AR-V7) expression was analyzed by western blot after treatment by
compound I with MG132 or without. The experiment was repeated three times
independently and the representative image and quantification are shown. Data are
expressed as Means ± SD (n=3). **p < 0.01 compared to DMSO treatment by unpaired t
test. #p < 0.05, ##p < 0.01 combination compared to only compound I treatment by
unpaired t test.
3.3.7. Compound I also suppresses AR transcription in GBM cells

We demonstrate that inhibiting HSP27 could downregulate AR through proteasome
pathway to accelerate the protein degradation directly. The results from the combination
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of compound I and MG132 suggest that AR might be regulated in multiple mechanisms

by compound I, since MG132 could not fully reverse the effect of compound I. Therefore,
we examined the mRNA of AR and the AR downstream gene PSA and NKX3.1 as well

(Figure 10). The results listed here indicate that AR downstream gene PSA and NKX3.1
are significantly suppressed by compound I at 25 nM, which is consistent to the low AR

protein level. Lower level of AR could not effectively activate the androgen response
element (ARE) and initiate the transcription. Interestingly, AR is also suppressed via
transcriptional regulation by compound I, and AR mRNA is down regulated significantly

at 25 nM. The lower level of AR mRNA after the treatment of compound I is a new
phenomenon, which has not been reported with HSP27 inhibition. It is possible that the

downregulation of AR transcription is not the targeting effect of HSP27 inhibition. It is
common that small molecule has off target effect. In this case, compound I might affect

other pathways to decrease AR transcription, which needs further investigation in the

future.
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Figure 10. Transcriptional regulation of AR related gene expression. The cells were
treated with compound I for 12 h and the RNA was extracted. AR, PSA, NKX3.1 gene
expression was examined with real time PCR. The results in T98G cells (A) and U87
cells (B) are shown with the quantification results. Data are expressed as Means ± SD
(n=3). *p < 0.05, **p < 0.01 compared to DMSO treatment group by unpaired t test.

3.3.8. Dihydrotestosterone (DHT) dissociates AR from HSP27 and decreases
compound I induced AR degradation

AR initiates its biological function via testosterone binding and then translocases

into nucleus to activate ARE. When AR is in the nucleus, the HSP27-AR complex is
broken, and AR degradation could only resume when AR is out of the nucleus. To
examine if HSP27-AR cooperation exists as we hypothesized in GBM, we used DHT to
force AR translocating into the nucleus, which is a well-used method to initiate AR

35

transcription activity. By this approach, HSP27-AR complex will be temporarily broken,

since HSP27 will not enter nucleus to continue stabilizing AR. Immunofluorescence
staining method could be used to examine the interaction of HSP27 and AR. We observe
that in T98G cells, AR is distributed in both the nucleus and cytosol in control group

(Figure 11), which is due to the androgen residual in the cell culture medium. Part of the
AR could be shuttled into the nucleus by the low level of androgens. HSP27 is distributed
around the nucleus in the cytosol. When compound I is applied, AR level is significantly
lower compared to the control group. This is consistent to the results of the western
blotting assay, and compound I induces AR degradation via HSP27 inhibition. When

DHT is applied, all the AR is concentrated in the nucleus and there is no distribution of

AR in the cytosol anymore. The results suggest that the AR in GBM is sensitive to ligand
DHT and responses to androgen stimulation very well. The high level of AR condensed

in the nucleus disrupts HSP27-AR complex, because HSP27 does not distribute in

nucleus. When DHT and compound I are combined, it is observed that the AR level in
the nucleus is similar to only DHT treatment, suggesting that the HSP27-AR complex

disruption eliminates the AR degradation induced by compound I. The results further
demonstrate that compound I induce AR degradation through HSP27-AR axis. The same
phenomenon could be observed in U87 cells as well.
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Figure 11. The expression and location of AR and HSP27 after T98G and U87 cells
treated with compound I or DHT or combination, then the cells were analyzed by
immunofluorescence assay.
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3.3.9. Compound I inhibits tubulin polymerization via interfere with colchicine
binding domain

This group of compounds were initially found binding to both HSP27 and tubulin 47.

We observed that compound I inhibits HSP27 and induces AR degradation, and it shows
selectivity to AR overexpressed GBM cells (Table 1). However, compound I also

inhibits the proliferation of GBM cells without AR expression, suggesting that the
compound has general activity against GBM cells. This broad cell growth inhibition

activity is unlikely to be correlated to the AR degradation. A more general target of
compound I might be responsible for the general cell growth inhibition. Herein, we

examine the tubulin polymerization inhibition activity of compound I (Figure 12). The

results exhibit that compound I dose-dependently inhibits tubulin polymerization in the in
vitro enzyme assay. The result is consistent to our previous studies that the compound I is

a dual inhibitor to HSP27 and tubulin 48,49, although it is more selective to AR
overexpressed T98G cells due to the AR downregulation activity via HSP27 inhibition.
In terms of potency for the inhibition of tubulin polymerization, compound I at 1 μM is

much more active than the positive control nocodazole, suggesting that compound I is
also a potent tubulin inhibitor as a cancer therapeutic agent.

A docking study reveals that compound I is able to occupy the binding pocket of

colchicine binding domain of tubulin. As can be seen from Figure 13, compound I binds
to the colchicine binding site in tubulin (1SA0.pdb) 58. Major hydrogen bond interactions

can be seen between the sulfonamide moiety and ALA316, and LYS352. Also, a

hydrogen bond is seen between a nitrogen and SER178. The binding model supports the
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ability of compound I to destabilize normal tubulin function, and the ability of compound

I to act as a possible chemotherapeutic agent.

Figure 12. Tubulin polymerization in the presence of different concentrations of
compound I and positive control nocodazole. DMSO is used as a negative control. The
results are representative of three independent experiments and the mean value was used
to generate the curve. The statistical analysis was performed with the end reading of the
curve with unpaired t test, **p<0.01 with compound I vs. control.
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Figure 13. Interaction of compound I with tubulin at the colchicine binding pocket
(1SA0.pdb). A) Dimer of tubulin shown as blue and pink, with compound I shown as
space fill; B) binding pocket of compound I with solvent accessible surface shown; C)
2D ligand interaction plot with key amino acids contributing to the hydrogen bonding
interactions.

3.3.10. Compound I does not inhibit cyclooxygenase 2 (COX-2)

Compound I is a promising drug candidate for potential treatment of AR

overexpressed GBM. From the drug design point of view, we removed the initial Nmethyl group of compound I, which actually was introduced to eliminate the COX-2
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inhibition function of the very original lead compound nimesulide 26. the ionization of the
sulfonamide moiety of nimesulide is critical for the COX-2 inhibition. With a Pka of 5.93,

the majority of nimesulide is ionized to form the negative charge, which is a key factor

for COX-2 binding. Introducing N-methyl group blocks the ionization and eliminate the

COX-2 inhibition, which has been demonstrated in our previous study 26. However, the

current investigation reveals that removing the methyl group could reduce in vivo toxicity
and also improve solubility. There is a concern that whether removing this methyl group

could bring COX-2 inhibition back. To clarify this potential problem, we measured the
COX-2 inhibition of the compound using prostaglandin E2 production assay (Figure 14).
U87 cells were treated with compound I and nimesulide for 12 h. The cell culture
medium was collected to determine the prostaglandin E2 level. The results show that

prostaglandin E2 levels are significantly decreased compared to DMSO (33.03 ±6.03

pg/mL) with nimesulide (7.66 ± 1.18 pg/mL) as indicated in Figure 14, while there is no

significant difference for compound I to control (35.33 ± 7.95 pg/mL). The results
suggest that removing of the methyl group does not affect the COX-2 inhibition of
compound I. It is speculated that the nitro group of nimesulide is critical to the COX-2

inhibition as well. In compound I, the nitro moiety is reduced to amino and formed a new
benzamide moiety, and this changing leads to the change of the Pka of compound I to
8.65. at physiological pH condition, compound I will not form negative charge anymore,

which could eliminate the COX-2 inhibition as well. Therefore, the methyl group of the
sulfonamide moiety is not critical for COX-2 inhibition anymore.
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Compound I Pka 8.65

Figure 14. Compound I does
were treated with nimesulide
was collected and the PGE2
Means ± SD (n=3). **p < 0.01

not change Prostaglandin E2 (PGE2) production. U87 cells
(10 μM) and compound I (10 nM) for 12 h, the medium
level was examined with ELISA. Data are expressed as
compared to DMSO treatment group.

3.3.11. Compound I significantly reduces the growth of human GBM and AR level
in the xenograft tumor model

As a potential drug candidate, it is critical to determine the in vivo activity of
compound I with the GBM model. In order to investigate the compound, the xenograft

tumor mouse model was established by subcutaneously injecting U87 cells into the left
and right flank of nude mice. Unfortunately, we did not successfully form a xenograft

model with T98G cells with the same procedure. After U87 tumor reached 200 mm3,
compound I was administrated into mice via intraperitoneal injection (IP) and oral every
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other day for 2 weeks and tumor volume and mice weight were measured. As shown in
Figure 15 A, mice body weight is not affected by the compound I treatment either with

IP or oral administration, which is consistent to the toxicity study (Figure 5). The tumor
size of compound I with both IP and oral administration is significantly (p<0.05)

decreased compared with the DMSO group (Figure 15 B), and the tumor weight of
compound I with IP injection is significant decreased compared with the DMSO group

(Figure 15 C). Unfortunately, due to the variability of the tumor with oral administration,
the tumor weight does not reach statistical significance compared to control. To confirm

that tumor inhibition effect is correlated with AR protein, AR expression level in tumor

was examined via western blotting (Figure 15 D). AR expression in both IP and oral
administration groups for the compound I treatment is significantly (p<0.01) decreased

compared with the DMSO group. The results demonstrate the great in vivo activity of
compound I in the animals and provide strong evidence that compound I is a promising

new drug candidate to treat AR overexpressed GBM.

43

Figure 15. In vivo efficacy of compound I in human glioblastoma. A total of 5 ×106 U87
cells were inoculated subcutaneously into nude mice, which were randomly assigned to
DMSO and compound I treated group. Nude mice were treated with compound I at 20
mg/kg with IP injection and oral administration. Body weight (A, n=4); tumor size (B,
n=8, data are expressed as Means ± SD. Oral ##p < 0.01, IP **p < 0.01 compared to
DMSO treatment group); tumor weight (C, n=8, data are expressed as Means ± SD. *p <
0.05 compared to DMSO treatment group) were measured and recorded; AR expression
in tumor was analyzed by western blot, shown by representative images and by
quantification (D, n=4, data are expressed as Means ± SD. *p < 0.05 compared to DMSO
treatment group).
3.4. Conclusion

GBM is the most aggressive and malignant primary human brain cancer with high
mortality rate 59. It is reported that a higher incidence rate happens in men compared to
women (3:2) 33,34,36, indicating that there is a sex disparity of the disease, which may be

correlated with different sex hormone pathways 60. Further studies reveal that AR

overexpression and mutation of AR are frequently observed in human GBM and
suppressing AR expression could induce GBM cells death in vitro and in vivo 59,61. AR

plays an important role in GBM progression. It is well known HSP27 is a chaperone
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protein that could stabilize AR. Targeting HSP27 to downregulate AR becomes a novel
approach for the treatment of AR overexpressed GBM. We aim to develop small

molecule HSP27 inhibitor as potential drug candidates to abolish AR in GBM, and
mutated AR could be eliminated in this strategy as well, which makes this approach

superior to other anti-androgen compounds. Compound I shows great potency and
selectivity to inhibit AR overexpressed GBM cells. It inhibits HSP27 chaperone function,
and induces AR degradation, which is correlated to the selectivity to AR overexpressed

cells. The compound also inhibits tubulin polymerization, therefore shows general
activity to inhibit cell proliferation. Compared to a similar analog with an extra N-methyl

group, compound I shows lower toxicity to mice. The removal of N-methyl group does
not bring the COX-2 inhibition back to the compound, suggesting that after the reduction

of the nitro group in the very lead compound nimesulide, the COX-2 inhibition is

eliminated in this scaffold. In addition to the HSP27 and tubulin inhibition, compound I
also affects AR transcription with an unknown mechanism, since the mRNA of AR is
also decreased after the treatment. It seems that the compound suppresses AR in GBM
with multiple mechanisms. The in vivo study reveals that compound I inhibits U87
xenograft and abolishes the AR in the tumor samples as well after the treatment. All the

in vitro and in vivo activity demonstrate that compound I is a promising drug candidate
for AR overexpressed GBM.
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CHAPTER IV

PHARMACOKINETIC AND BRAIN DISTRIBUTION STUDY OF AN ANTI
GLIOBLASTOMA AGENT IN MICE BY HPLC-MS/MS

4.1. Introduction

GBM is a common brain cancer and is considered the most aggressive malignant
brain cancer in adults. The prognosis of GBM remains poor even when the combination

treatment of chemotherapy and radiotherapy were performed after surgical removal of the
tumor 4. The median survival rate of the patients is about 15 months with the treatment
because of the high recurrence rate and resistance to therapeutics 2. TMZ, an oral

alkylating chemotherapy prodrug, is often used after surgical resection in the current
treatment 5. However, the recurrence usually occurred months after the TMZ treatment.
Therefore, there is an urgency to develop a new therapeutic approach for defending GBM.
Ever since the AR was first detected in astrocytoma in 1996 62, many studies

indicated that AR could be a potential target for the treatment of GBM. Testosterone
could stimulate the progression of GBM by promoting proliferation, migration and
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invasion via activating AR functions 59. Also, Zalcman et al revealed that siRNA induced

AR gene silencing induced GBM cell death, while enzalutamide (AR antagonist) reduced
the GBM tumor growth in nude mice

27.

However, the AR mutation (AR-V7), which

commonly occurred in GBM, causes the AR antagonist agents to be less effective

63.

HSP27 is a well-documented chaperone protein to stabilize AR 60,64,65, and inhibition of
HSP27 results in AR degradation regardless of the mutation 10. Thus, HSP27 suppression
could be a novel approach for AR overexpressed GBM treatment.
Compound I (Figure 16), a HSP27 inhibitor, has been identified to abolish AR in

GBM 29. Compound I could significantly downregulate AR and AR-V7 at 50 nM, and the
IC50s to inhibit GBM cell growth could reach 5 nM. Moreover, compound I could inhibit

GBM tumor growth in the mice xenograft model, and does not cause toxicity to animals

even at much higher doses. Compound I could be the potential drug candidate treat GBM.
However, whether compound I could cross BBB is a critical factor to consider for the

treatment of GBM. Thus, a pre-clinical pharmacokinetic investigation and brain tissue
detection of compound I is urgently needed to determine the pharmacokinetic profiles of
compound I. In the present study, a sensitive and reliable HPLC-MS/MS method was

established and validated for the determination of the concentrations of compound I in
mice plasma and brain tissue. The method was successfully applied to the
pharmacokinetic study of compound I in mice after intraperitoneal injection.
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4.2. Materials and methods

4.2.1. Chemicals and reagents

Compound I and internal standard (IS) compound 14 (Figure 16) were prepared

and characterized according to published methods 48. MS-grade acetonitrile and ACS-

grade methanol were purchased from Sigma-Aldrich (St. Louis, MO, USA), and LC/MSgrade formic acid was purchased from Fisher Scientific (Waltham, MA, USA). Double
Deionized water was prepared by Barnstead Nanopure® water purification system from
Thermo Scientific (Waltham, MA, USA).

4.2.2. Animals
C57BL/6 mouse (36 males, 20-25 g) bred from the animal facility of Cleveland

State University were used for the study. All the mice were given free access to water, a
standard laboratory diet, and maintained under standard conditions (25 °C ±2 °C, 12 h dark
light cycle, 50%±10 % humidity) in accordance with the institutional guidelines for

Animal Research Facilities. All mice fasted overnight but were allowed free access to

water before the drug injection.

4.2.3. Instrumentations and HPLC-MS/MS conditions

The HPLC-MS/MS method was performed with a Shimadzu UPLC system
(Columbia, MD) which consisted of a Prominence DGU-20Asr inline degasser, two LC30 AD pumps, a SIL-30 AC autosampler and a CBM-20A controller. The

chromatographic separation was performed on a Kinetex C18 column (50 mm × 2.1 mm,
1.3 μm) with a mobile phase consisting of acetonitrile-0.1% formic acid and water (50:50,
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v/v) at a flow rate of 0.3 mL/min. The temperature of the column was maintained at 36°C.

The injection volume was 5.0 μL.
Mass spectrometric detection was operated on an AB Sciex Qtrap 5500 mass

spectrometer (Toronto, Canada) with negative electrospray ionization mode. The multiple
reaction monitoring (MRM) function was used for quantification with the transitions of
compound I and IS compound 14, which were detected at m/z 485.1 →256.1 and m/z

499.2→268.2, respectively. The proposed fragmentation pathways of compound I and
compound 14 are shown in Figure 16. The optimized ion source parameters were set as

follows: ion spray voltage, -4200 V; temperature e, 450°C; heating gas, nebulization gas,

curtain gas, 40 psi. Compound parameters were as follows: declustering potential, -100 V;
entrance potential, -10V; collision energy, -35V for compound I, -40 V for compound 14;
collision exit potential, -15 V for compound I, -20 V for compound 14. Data acquisition

and quantification were performed using analyst software (version 1.6.2).

4.2.4. Preparation of standards and samples

4.2.4.1. Preparation of stock and working solution
The stock solutions were prepared by dissolving compound I and compound 14 in
methanol at 1.0 mg/mL. Then, the stock solution of compound I was serially diluted with
methanol into a concentration gradient: 1.0, 2.0, 5.0, 10, 20, 50, 100, 200, 500, 1000

ng/mL. Also, a 250 ng/mL working solution of compound 14 (IS) was prepared in
methanol from the stock solution of compound 14. All the solutions were stored at 4°C in
the dark.
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4.2.4.2. Preparation of calibration standards and quality control
The calibration standards were prepared as follows: After spiking with 100 μL of
the corresponding standards solutions, 40 μL of compound 14 working solution, 100 μL

of blank mouse plasma (collected and mixed from 6 mice) or brain homogenates (0.4 g of
6 blank brain tissues mixed with 2 mL PBS), and 800 μL of methanol were transferred

into a 1.5 mL tube, the mixture was then vortexed and centrifuged at 12,000 g for 10
mins. The supernatant was collected and transferred into a new 1.5 mL tube. After being
dried with nitrogen, the residue was stored at -80°C and dissolved with 50% acetonitrile

before analysis. Also, the quality control (QC) samples were independently prepared with
same blank mouse plasma or brain homogenates. The preparation method was the same
as the calibration standards. The QC samples were prepared at concentrations of 2 ng/mL

(low), 50 ng/mL (medium) and 200 ng/mL (high) and were then divided into aliquots and
stored in the freezer at -80 °C before analysis.

4.2.4.3. Preparation of samples
A simple protein precipitation method was applied to extract compound I from

mouse plasma or brain homogenate (0.4 g brain tissue mix with 2 mL PBS). Briefly, 100

μL of each sample, 40 μL of compound 14 (IS, 250 ng/mL), and 800 μL of methanol
were combined in a 1.5 mL tube. Then, it was vortexed and centrifuged at 12,000 g for 5
min. The supernatant was collected and then transferred into a new 1.5 mL tube. The

liquid was dried by a nitrogen blowing instrument. The residue was stored at -80 °C and

dissolved with 100 μL 50% acetonitrile before analysis.
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4.2.5. Method validation

In accordance with the FDA bioanalytical method validation guidance, the HPLC-

MS/MS method was validated in terms of selectivity, linearity and sensitivity, precision
and accuracy, matrix effect, and recovery and stability 66.

4.2.5.1. Selectivity
The selectivity was determined by testing the blank plasma from six mice or blank
brain tissue homogenate, blank matrices spiked with IS only, and plasma and brain
samples obtained from mice dosed with compound I.

4.2.5.2. Linearity and sensitivity
The linearity of this method was examined via analysis of the standard curve

containing ten different concentrations (1-1000 ng/mL). The standard curve was obtained
by plotting the peak area ratios (compound I/compound 14, Y-axis) versus the

concentrations (X-axis) of compound I and assessed by weighted least-squares linear
regression using 1/x2 as the weighting factor. The lowest concentration (1.0 ng/mL) was
considered as the lower limit of quantification (LLOQ).

4.2.5.3. Precision and accuracy
The precision and accuracy were investigated with the QC samples in 5 replicates,
which were prepared and analyzed on three continuous days. The intra and inter-day

precision was represented as the RSD and the accuracy was expressed as RE.

4.2.5.4. Extraction recovery and matrix effect
Extraction recovery was measured by calculating the ratio of the responses of QC

samples spiked with analytes prior to extraction and the responses of those spiked with

protein precipitated blank plasma or brain homogenates. The matrix effect was evaluated
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by measuring the ratio of the responses in blank plasma or brain homogenates and those

dissolved with 50% acetonitrile (v/v) at the same concentration. Generally, the extraction
recovery should be over 85% and the matrix effects should be less than 15% according to
FDA guidance for methodology development.

4.2.5.5. Stability
The stability was evaluated by testing five replicates of the samples at three QC
levels under different conditions (24 h storage at room temperature, three freeze/thaw

cycles and storage at -80°C for 30 days). The samples are considered stable if the average
percentage concentration deviation is within 15% of the actual value.

4.2.6. Pharmacokinetic study

A dosing solution (5 mg/mL) of compound I was prepared in preclinical
formulation vehicle [5% Cremophor EL (CrEL) with PBS]. The mouse received a 100

mg/kg dose of compound I by intraperitoneal (IP) administration. 400 μL mouse blood
samples and the whole brain tissue were collected at each time point by euthanizing the

treatment group of mice at 0.083 h, 0.25 h, 0.5 h, 1.0 h, 2.0 h, 4.0 h, 6.0 h, 12 h, 24 h,
respectively. The blood was directly collected from heart, then followed by perfusion
with PBS and brain tissue was collected consequently. The blood samples were

centrifuged immediately at 3,000 g for 10 min at 4°C, and the supernatant plasma were
collected, and immediately stored at -80°C until analysis. The brain tissue was weighted
out and mixed with PBS (1:5, m/v) in Dounce Tissue Grinders (DWK Life Sciences),

homogenized on ice. Then, aliquots of the homogenates were immediately frozen and
stored at -80°C until analysis.
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4.2.7. Data analysis

The plasma and brain homogenates samples were subjected to HPLC-MS/MS
analysis as above and the concentrations of compound I were calculated according to the
calibration curve. Microsoft Excel 2020 (Microsoft Co., USA) was used to calculate the

pharmacokinetic parameters. GraphPad Prism 5.0 (GraphPad Software, USA) was used
to plot the concentration-time curve. All the results were expressed as Mean ± SD.
4.3. Results and discussion

4.3.1. Optimization of chromatography conditions and MS conditions

The chromatographic condition was optimized to improve peak shape, increase
signal response of analysts, and shorten retention time. In the current chromatographic

separation, a Kinetex C18 column was used to separate the analytes. The composition of
the mobile phase, especially the organic phase, was optimized in order to acquire good

chromatographic separation. Compared with methanol-water, it was found that
acetonitrile-water obtained higher peak shape. The signal response was significantly

improved with 0.1% formic acid added into the water phase. Eventually, acetonitrile-

0.1% formic acid and water (50:50, v/v) was adopted as the mobile phase at a flow rate of
0.3 mL/min. Under the optimized condition, sharp peaks of analyte and internal standard

are acquired with the consistent separation. The retention time was 1.51 min for
compound I, 1.88 min for compound 14, respectively.

In order to optimize the mass spectrometer parameters, 200 ng/mL of compound I
and 100 ng/mL of compound 14 in acetonitrile-0.1% formic acid and water (50:50, v/v)
were injected into the mass spectrometer through direct infusion at 10 uL/min. Negative
modes of ESI was assessed for compound I and compound 14 (Figure 16). ESI (-) was
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used for the study. The results showed that the predominant deprotonated molecular ions

[M-H]- were m/z 485.1 (compound I) and m/z 499.2 (compound 14). The multiple
reaction monitoring (MRM) function was used for quantification of the transitions of
compound I and internal standard compound 14, which were detected at m/z

485.1→256.1 and m/z 499.2→268.2, respectively.

Figure 16. Full-scan product ion spectrum and proposed fragmentation pathways of (A)
compound I and (B) compound 14 (IS).

4.3.2. Method validation

4.3.2.1. Selectivity
Selectivity was used to evaluate the potential interference of endogenous
substances to the detection of analytes. In this present study, the retention time was 1.51

min for compound I, 1.88 min for compound 14, respectively. Both of the analyte and
internal standard showed well-separated peaks with no significant interference from
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endogenous substances observed at their corresponding retention times under current
detection condition. Typical chromatograms of blank mouse plasma or brain, blank

plasma or brain homogenates spiked with IS (compound 14, 100 ng/mL) and plasma and

brain samples from mice with IP administration of compound I in 5% CrEL at 0.5 h
shown in Figure 17.

Figure 17. Typical chromatograms of different samples (A) blank mouse plasma, (B)
mouse plasma spiked with IS (compound 14, 100 ng/mL) only, (C) plasma samples from
mice with IP administration of compound I in 5% CrEL at 1.0 h, (D) blank brain
homogenates, (E) brain homogenates spiked with IS (compound 14, 100 ng/mL) only,
and (F) samples from mice with IP administration of compound I in 5% CrEL at 1.0 h.

4.3.2.2. Linearity and sensitivity
The calibration curve of the ratio of analyte/IS peak area (Y) to the concentration (X)

was plotted via 1/x2 weighted linear least-square regression model. The calibration curve
of compound I in mouse plasma was Y=0.1234X+0.7208, which exhibited good linearity

(r = 0.990). The calibration curve of compound I in brain tissue was Y=0.1460X+0.4691,
which exhibited good linearity (r = 0.996). The LLOQ for compound I was determined to

be 1.0 ng/mL in all different mouse plasma and brain tissue samples.
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4.3.2.3. Precision and accuracy
The precision was demonstrated as the RSD of the QC samples at three
concentration levels (2, 50 and 500 ng/mL) while the accuracy was expressed as RE. The
precision of intra- and inter-day accuracy are shown in Table 3. The RSD of Intra-day
and Inter-day for precision are less than 3.85% and 8.29%, respectively. The RE for

accuracy was within ± 7.33%. The results showed that the method was acceptable for

precision and accuracy.

Table 3. Intra- and inter-assay precision, accuracy for the determining compound I in
mouse plasma and brain tissue (n = 3 days, 5 replicates per day).________________
Analyte
Intra-day
Inter-day
Accuracy
Samples
concentration
(RSD %)
(RE%)
(RSD %)
(ng/mL)

Plasma

Brain

2

1.80

8.29

-5.88

50

2.05

4.41

-6.16

200

2.77

4.50

3.12

2

1.81

4.85

6.21

50

1.24

4.55

-5.54

200

3.85

7.77

-7.33

4.3.2.4. Extraction recovery and matrix effects
Extraction recovery and matrix effects of QC samples from mouse plasma and

brain tissue at three different concentrations (2, 50 and 200 ng/mL) were evaluated. The

results are listed in Table 4. The results showed that the extraction recoveries were over
93.16% for three different levels of QC samples. The results indicated that this extraction

method was qualified for the requirement of quantification of compound I plasma and
brain sample drug concentration determination. The matrix effects at three concentrations
were within 92.24-111.24%, indicating minor matrix effects.
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Table 4. Extraction recovery and matrix effect of compound I in mouse plasma and brain
tissue (n=5).
Extraction
Matrix effect
RSD
Samples
Analyte
RSD
recovery
concentrations
(%)
(%)
(%)
(ng/mL)
(%)

Plasma

Brain

2

93.16±12.86

13.80

96.23±6.30

6.55

50

105.30±2.57

2.44

104.22±5.42

5.20

200

95.02±4.46

9.74

92.37±10.43

11.29

2

110.54±12.95

11.71

92.24±7.23

7.84

50

110.15±8.88

8.06

99.38±9.11

9.17

200

117.45±13.54

11.53

111.24±10.42

9.37

4.3.2.5. Stability
The stability of compound I in mouse plasma and brain homogenates was
investigated by measuring the concentration of compound I in QC samples with three

different storage conditions, including three freeze-thaw cycles, maintenance at room
temperature for 24 h (short term) and at -80°C for 30 days (Long term). The results are

shown in Table 5. The RE of compound I in mouse plasma and brain homogenate at
three different level QC samples were both less than 8.7%. Compound I was found to be

stable in mouse plasma and brain homogenate after three freeze-thaw cycles and after
storing at room temperature for 24 h and -80 °C for 30 days.
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Table 5. Stability of compound I in mouse plasma and brain tissue (n=5)
Samples

Plasma

Brain

Analyte
concentration
(ng/mL)

Three freeze
thaw cycles

Room
temperature for
24 h

Long term
(30 days, -80oC)

RSD %

RE %

RSD %

RE%RE %

RSD %

RE %

2

11.59

-8.7

9.56

6.1

12.44

7.5

50

9.97

5.8

10.21

-2.7

8.63

-6.4

200

8.66

-3.5

6.64

6.5

6.76

5.6

2

8.45

5.7

8.14

-3.8

4.87

5.9

50

8.58

7.2

10.51

-4.4

12.42

7.8

200

8.51

4.5

5.71

-5.5

9.52

7.1

4.3.3. Pharmacokinetic study and brain tissue determination

The validated HPLC-MS/MS method was successfully used to evaluate the
concentration of compound I in mouse plasma and brain tissue after IP dose (100 mg/kg).

The mouse plasma and brain tissue concentrations of compound I at different dosing
times are exhibited in Figure 18. The pharmacokinetic parameters are listed as Mean ±
SD in Table 6. The results showed that compound I was rapidly absorbed and distributed

and the Cmax was achieved within 1.0 h. The apparent elimination half-life (t1∕2) was 4.06

h, indicating compound I could be cleared fast from the mouse plasma. Also, Cmax of
compound I in mouse plasma reached to 68.97 μg∕mL. Moreover, the compound I was

detected in brain tissue after IP administration, the Cmax of compound I in brain tissue is

0.88 μg/g (1%-2% of the concentration in blood), indicating that part of compound I in
the blood circulation was able to pass the blood-brain barrier (BBB) and accumulate in
the brain tissue (Figure 18 C & D).
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Figure 18. Plasma (A and B) and brain (C and D) tissue concentration-time profiles of
compound I with IP administration in mice. (Mean ± SD, n=4)

Table 6. Non-compartmental pharmacokinetic parameters of compound I in mouse after
IP administration (n=4, Mean ± SD)._____________________________________
Pharmacokinetic
Value
parameters

Plasma

Brain

t1/2

4.06±1.65 (h)

3.24±0.62 (h)

Cmax

68.97±6.66 (μg∕mL)

0.88±0.85 (μg∕g)

AUC0-24h

65.44±37.35 (μg.h∕mL)

1.54±0.81 (μg.h∕g)

AUC0-∞h

77.96±20.42 (μg.h∕mL)

1.66±0.78 (μg.h∕g)

4.4. Conclusions

A reliable and sensitive HPLC-MS/MS method for the quantification of compound

I in mouse plasma and brain tissue was developed. The method was accurate, efficient,
reliable, and successfully applied for evaluation of the pharmacokinetics of compound I

in the in vivo study. The results indicated that compound I was rapidly distributed.
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Moreover, compound I could across the BBB, which indicates the compound could be

delivered to the central nervous system. The pharmacokinetic profile summarized in the
study provides valuable information for the further investigation of compound I as a
potential anti-glioblastoma agent.
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CHAPTER V
SYNTHESIS AND ANTI-GLIOBLASTOMA EFFECT EVALUATION OF HSP27

INHIBITORS

5.1. Introduction

GBM is the most common and aggressive brain tumor, with about 12,000 cases

diagnosed in the United States annually 1,2. The prognosis of GBM remains poor, despite
with the advanced new surgical techniques combined with radiotherapy and

chemotherapy 4. The median length of survival after a diagnosis is 15-18 months 2. The
current mainstay of treatment for GBM patients is surgery, followed by radiation therapy
with temozolomide (TMZ, an oral alkylating chemotherapy medicine) 31. However, GBM

usually reoccurs within couple months after the surgery. Identification of new molecular

targets to develop more effective drugs for GBM treatment is very urgent, the current

treatment protocol caused the low median survival rate for GBM patients.

The epidemiological survey has demonstrated that the incidence of GBM in men is

1.6 folds higher than that in women, indicating that sex related diversity 24,33. Also, many
recent researchers indicated that androgen plays an important role in the development of
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GBM 36. It has been well established that androgen plays a vital role in the development
of male phenotype, also exert the biological functions via association with androgen
receptor (AR) 67. Recently, many studies claimed that AR is overexpressed in GBM and
androgens contribute to the GBM progression 27,29,39. Thus, targeting AR might be a

potential approach in GBM treatment. Androgen does promote GBM proliferation,

migration and invasion via AR activation 59. Seviteronel, as a nonsteroidal anti androgenic

agent, has been investigated in clinical trials for AR-overexpressed GBM patients 68. AR
antagonists, Enzalutamide and Bicalutamide, could inhibit the proliferation of GBM cells

in vitro and in vivo 27,69. However, mutated AR (AR-V7), which lacks the binding domain
becomes resistant, and was identified in about 30% of GBM surgical specimens, among
to the wild-type AR 63, which suggests that the activity of AR targeting agents was

restricted in the GBM treatment. It is urgent to develop an alternative approach to
suppress AR activity in GBM.

Heat shock proteins play an important role in the folding, activation and regulation
of transcriptional activity of steroid hormone receptors 60. Over expression HSP27
enhance the stability of its client proteins and prevent cell death from a variety of stress 41.

It is well known that AR is one of the client proteins of HSP27 and HSP27 escorts AR
translocation into the nucleus to trigger androgen response elements (ARE) gene

regulation 28,41. HSP27 is responsible for AR stability and seems to be a good direct target
for HSP27-AR pathway in GBM. Currently, the most effective approach to target HSP27

is antisense oligonucleotides (ASO) or short interfering RNA (siRNA), which could
decrease HSP27 expression in in vitro and in vivo 70,71. However, ASO and siRNA are
not applicable to GBM because of the poor BBB permeability. Thus, small-molecule
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HSP27 inhibitors could be a promising strategy to induce AR degradation in GBM, since
small molecules have strong potential to pass BBB.

Previously, we identified compound I as a dual HSP27 and tubulin inhibitor, it
exhibited significant activity to inhibit GBM growth in vitro and in vivo 29. The IC50s of
compound I against the proliferation of the four glioblastoma cell lines (T98G, U87,

A172, U251) were less than 10 nM. Also, the tumor size was significantly shrunk and AR
level in tumor was also decreased with compound I treatment in xenograft model 29. The
previous results demonstrated that compound I is a promising new drug candidate to treat

AR-overexpressed GBM. However, the previous pharmacokinetic study results showed
that area under concentration-time curve (AUC) of compound I in brain tissue was only

2% of AUC in plasma 72. This result indicated that compound I could cross the blood
brain barrier, but with very limited permeability. In this study we set out to identify a
HSP27 inhibitor with higher activity to treat AR overexpressed GBM with higher

permeability to brain tissue, 42 derivatives (5 dimers included) were synthesized based
on compound I as the lead compound. Among the new candidates their HSP27 inhibition

activity increased as well as an improved BBB penetration and potent in vivo activity.
5.2. Materials and Methods

5.2.1. Reagents

Thiazolyl Blue tetrazolium bromide, 98% (Alfa Aesar, P31B064). Insulin (Sigma
Aldrich, 91077C). α-crystallin (Sigma Aldrich, C4163). Dithiothreitol (DTT) (Amresco,
EC# 222-468-7). DMEM (Corning, 10-013-CV). RPMI 1640 (Corning, 10-040-CV).

FBS (Atlanta Biologicals, S11150). Pen/Strep solution (Cleveland Clinic, 725-100p).
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Anti-β-actin antibody (Cell Signaling Technology, 4967S). Bovine serum albumin

(Millipore Sigma, 2905-OP). RIPA (Thermo Scientific, Prod# 89900). Protease inhibitor

cocktail (Thermo Scientific, Prod# 1861278). BCA Protein Assay kit (Biovision, Prod#
K813-2500-1). Anti-HSP27 antibody (Cell Signaling Technology, 2402S). Anti

Androgen Receptor antibody (Cell Signaling Technology, 5153S). Anti-AR-V7 antibody
(Cell Signaling Technology, 68492S). Anti-Rabbit IgG (Cell Signaling Technology,
7074S). Anti-Rabbit Alexa Fluor 488 secondary antibody (Thermo Scientific, A-21206).

Anti-Mouse Alexa Fluor 594 secondary antibody (Thermo Scientific, SA5-10168). Non
Fat dry milk (Rockland, B51-0500). Chemiluminescent Substrate (Thermo Scientific,

34577). Hematoxylin solution (Harris, VWR Internationals, 95057-844). Eosin solution
(VWR Internationals, 95057-848). All the other chemicals are analytical grade.

5.2.2. Chemistry

Chemicals were commercially available and used as received without further

purification unless otherwise noted. Thin layer chromatography (TLC) was performed on

silica gel TLC plates with a fluorescence indicator at 254 nm (Analytikjena). Mass
spectra were obtained on a Shimazu Single Quad Mass spectrometer at Cleveland State

University MS Facility Center. All NMR spectra were recorded on a Bruker 400 MHz

spectrometer using DMSO-d6 as the solvent.
Reversed phase HPLC analysis of compounds was conducted on a Beckman HPLC

system with an Auto Sampler. The chromatographic separation was performed on a a
Kinetex C18 column (50 mm × 2.1 mm, 1.3 μm) with a mobile phase consisting of

acetonitrile-0.1% formic acid and water (80:20, v/v) at a flow rate of 0.3 mL/min. The
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temperature of the column was maintained at 36°C. The injection volume was 5.0 μL.

The reaction procedure is illustrated in Scheme 1. The final step of the reaction and the
product characterization are listed below.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3,5-bis(trifluoromethyl)

benzamide (1). Yield 32%, White Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.60 (s,
1H), 9.06 (s, 1H), 8.62 (s, 2H), 8.40 (s, 1H), 7.66 (s, 1H), 7.44 (d, J= 8.6 Hz, 1H), 7.30

(m, 2H), 6.98 (d, J= 8.9 Hz, 1H), 6.88 (d, J= 3.9 Hz, 1H), 5.11 (s, 2H), 3.79 (s, 3H), 3.74
(s, 3H), 2.90 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δo 163.00, 153.68, 153.01, 150.97,

138.22, 137.48, 131.47, 131.14, 130.80, 129.04, 128.35, 125.73, 124.95, 122.23, 115.20,
113.79, 113.33,

112.08,

106.04, 65.52, 56.24, 55.91. ESI-MS calculated for

(C25H22F6N2O6S) [M-H]-: m/z 591; Molecular Weight (calculated from structure): 592.51.

HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.85 min,
purity: >95%.

4-cyano-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide (2).

Yield 14%, Pale Yellow Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.52 (s, 1H), 9.00
(s, 1H), 8.12 (m, 2H), 8.05 (m, 2H), 7.69 (s, 1H), 7.43 (d, J= 8.5 Hz, 1H), 7.41 (s, 1H),

7.26 (d, 1H), 6.99 (d, J= 8.9 Hz, 1H), 6.90 (d, J= 8.9 Hz, 1H), 5.10 (s, 2H), 3.79 (s, 3H),
3.74 (s, 3H), 2.90 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δo 164.58, 153.67, 153.03,

150.96, 139.28, 138.60, 132.95, 128.98, 128.46, 125.76, 121.88, 118.77, 115.20, 114.40,
113.77, 113.03, 112.06, 105.79. ESI-MS calculated for (C24H23N3O6S) [M-H]-: m/z 480;
Molecular Weight (calculated from structure): 481.52. HPLC mobile phase: 80% ACN
with 0.1% formic acid, retention time 0.67 min, purity: >95%.
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4-chloro-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3-

nitrobenzamide (3). Yield 41%, Pale Yellow Powder. 1H NMR (400 MHz, DMSO-d6) 5h
10.58 (s, 1H), 9.04 (s, 1H), 8.64 (s, 1H), 8.28 (d, J= 8.4 Hz, 1H), 8.00 (d, J= 8.4 Hz, 1H),

7.65 (s, 1H), 7.43 (d, J= 8.6 Hz, 1H), 7.41 (s, 1H), 7.28 (d, J= 8.6 Hz, 1H), 6.99 (d, J=

8.9 Hz, 1H), 6.81 (m, 1H), 5.10 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.89 (s, 3H); 13C NMR
(100 MHz, DMSO-d6) δc 162.89, 153.68, 153.02, 150.95, 135.24, 133.30, 132.45, 128.60,

125.75, 125.30, 115.18, 113.77, 112.06, 105.86, 56.25, 55.92. ESI-MS calculated for
(C24H24N2O8S) [M-H]-: m/z 534; Molecular Weight (calculated from structure): 535.95.

HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.70 min,
purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzo[d][1,3]dioxole-5-

carboxamide (4). Yield 39%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.10 (s,
1H), 8.95 (s, 1H), 7.69 (s, 1H), 7.59 (d, J= 8.0 Hz, 1H), 7.52 (s, 1H), 7.41 (d, J= 8.9 Hz,
1H), 7.28 (s, 1H), 7.22 (d, J= 8.8 Hz, 1H), 7.07 (d, J= 8.0 Hz, 1H), 6.99 (d, J= 8.8 Hz,
1H), 6.90 (d, J= 8.9 Hz, 1H), 5.10 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.89 (s, 3H); 13C

NMR (100 MHz, DMSO-d6) δc 164.94, 153.70, 153.07, 151.01, 125.86, 123.33, 115.25,

113.83, 112.88, 112.11, 108.42, 108.15, 105.72, 102.31, 65.44, 56.27, 55.94. ESI-MS

calculated for (C24H24N2O8S) [M-H]-: m/z 499; Molecular Weight (calculated from
structure): 500.52. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time
0.70 min, purity: >95%.

3,5-dichloro-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide

(5). Yield 39%, Pale Yellow Powder. 1H NMR (400 MHz, DMSO-d6) δH 10.45 (s, 1H),
9.02 (s, 1H), 7.99 (s, 2H), 7.89 (s, 1H), 7.65 (s, 1H), 7.42 (d, J= 8.6 Hz, 1H), 7.24 (m,
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2H), 6.98 (d, J= 8.8 Hz, 1H), 6.90 (d, J= 6.8 Hz, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s,
3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 163.13, 153.68, 153.01, 150.98,

138.43, 134.81, 131.48, 128.38, 126.95, 125.75, 121.98, 115.21, 113.80, 113.09, 112.09,
105.86, 65.47, 56.26, 55.92. ESI-MS calculated for (C23H22Cl2N2O6S) [M-H]-: m/z 523;
Molecular Weight (calculated from structure): 525.40. HPLC mobile phase: 80% ACN
with 0.1% formic acid, retention time 0.67 min, purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3-iodobenzamide

(6).

Yield 25%, Yellow Powder. 1H NMR (400 MHz, DMSO-d6) δκ 10.34 (s, 1H), 8.99 (s,
1H), 8.30 (s, 1H), 7. 98 (d, J= 7.8 Hz, 2H), 7.65 (s, 1H), 7.40 (dd, J= 2, 8.5 Hz, 1H), 7.39

(d, J= 2.6 Hz, 1H), 7.28 (d, J= 8.6 Hz, 1H), 6.99 (d, 1H), 6.90 (d, J= 8.9 Hz, 1H), 5.08 (s,
2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.86 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δC 164.34,

153.68, 152.93, 150.96, 140.61, 137.30, 136.36, 131.06, 127.63, 115.20, 113.74, 113.08,
112.06, 95.16, 65.46, 56.25, 55.92. ESI-MS calculated for (C23H23IN2O6S) [M-H]-: m/z
581; Molecular Weight (calculated from structure): 582.41. HPLC mobile phase: 80%
ACN with 0.1% formic acid, retention time 0.67 min, purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3-fluoro-4-

(trifluoromethyl)benzamide (7). Yield 23%, Pale Yellow Powder. 1H NMR (400 MHz,
DMSO-d6) δH 10.62 (s, 1H), 9.01 (s, 1H), 8.01 (m, 2H), 7.55 (m, 2H), 7.29 (d, 3H), 6.99

(d, J= 9.0 Hz, 1H), 6.86 (m, 1H), 5.08 (s, 2H), 3.78 (s, 3H), 3.73 (s, 3H), 2.84 (s, 3H); 13C
NMR (100 MHz, DMSO-d6) δC 161.62, 153.67, 152.79, 150.97, 136.11, 129.62, 127.23,

126.03, 125.67, 115.17, 113.70, 112.64, 112.05, 105.65, 65.48, 26.25, 55.90. ESI-MS

calculated for (C24H22F4N2O6S) [M-H]-: m/z 541; Molecular Weight (calculated from
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structure): 542.50. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time
0.70 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-iodobenzamide

(8).

Yield 45%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.34 (s, 1H), 9.00 (s, 1H),
7.95 (d, J= 8.4 Hz, 2H), 7. 77 (d, J= 8.5 Hz, 2H), 7.68 (s, 1H), 7.42 (d, J= 8.6 Hz, 1H),
7.40 (s, 1H), 7.27 (d, J= 8.6 Hz, 1H), 6.99 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.08 (s, 2H),
3.79 (s, 3H), 3.73 (s, 3H), 2.87 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 165.22,

153.67, 153.03, 150.96, 138.74, 137.75, 134.62, 130.05, 128.38, 125.83, 121.82, 115.19,
113.75, 112.97, 112.05, 105.78, 99.86, 65.43, 56.24, 55.91. ESI-MS calculated for
(C23H23IN2O6S) [M-H]-: m/z 581; Molecular Weight (calculated from structure): 582.41.

HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.67 min,
purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-ethylbenzamide (9).

Yield 30%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.34 (s, 1H), 8.98 (s,
1H), 7.91 (d, J= 8.1 Hz, 2H), 7. 72 (s, 1H), 7.44 (d, J= 8.1 Hz, 1H), 7.42 (d, J= 8.6 Hz,

2H), 7.29 (s, 1H), 7.28 (d, J= 8.6 Hz, 1H), 6.99 (d, J= 8.9 Hz, 1H), 6.89 (m, 1H), 5.09 (s,
2H), 3.79 (s, 3H), 3.74 (s, 3H), 3.30 (d, 2H), 2.87 (s, 3H), 2.70 (t, 3H); 13C NMR (100
MHz, DMSO-d6) δc 165.22, 153.67, 153.03, 150.96, 138.74, 137.75, 134.62, 130.05,

128.38, 125.83, 121.82, 115.19, 113.75, 112.97, 112.05, 105.78, 99.86, 65.43, 56.24,
55.91. ESI-MS calculated for (C25H28N2O6S) [M-H]-: m/z 483; Molecular Weight

(calculated from structure): 484.57. HPLC mobile phase: 80% ACN with 0.1% formic
acid, retention time 0.67 min, purity: >95%.
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N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-

(dimethylamino)benzamide (10). Yield 20%, Gray Powder. 1H NMR (400 MHz, DMSO-

d6) 5h 10.34 (s, 1H), 8.95 (s, 1H), 7.89 (d, J= 8.9 Hz, 2H), 7. 73 (s, 1H), 7.40 (m, 1H),
7.29 (s, 1H), 7.18 (d, J= 8.6 Hz, 1H), 7.00 (d, J= 8.9 Hz, 1H), 6.90 (m, 1H), 6.78 (d, J=

8.9 Hz, 2H), 5.08 (s, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 3.01 (s, 6H), 2.86 (s, 3H); 13C NMR
(100 MHz, DMSO-d6) δc 1 165.65, 153.67, 153.16, 152.92, 150.96, 139.83, 129.60,
128.66,. 125.89, 121.33, 120.65, 115.21, 113.74, 112.65, 112.03, 111.24, 105.43, 65.35,

56.23, 55.91. ESI-MS calculated for (C25H29N3O6S) [M-H]-: m/z 498; Molecular Weight
(calculated from structure): 499.58. HPLC mobile phase: 80% ACN with 0.1% formic
acid, retention time 0.67 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3,4-

dimethoxybenzamide (11). Yield 27%, Pale Yellow Powder. 1H NMR (400 MHz,
DMSO-d6) 5h 10.34 (s, 1H), 8.99 (s, 1H), 7.71 (s, 1H), 7. 65 (d, J= 8.4 Hz, 1H), 7.54 (s,
1H), 7.40 (d, J= 10.6 Hz, 1H), 7.38 (s, 1H), 7.29 (d, J= 8.6 Hz, 1H), 7.11 (d, J= 8.5 Hz,

1H) 6.99 (d, J= 8.9 Hz, 1H), 6.87 (d, 1H), 5.08 (s, 2H), 3.85 (s, 6H), 3.79 (s, 3H), 3.74 (s,
3H), 2.87 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 165.37, 153.67, 153.11, 152.21,

150.96, 148.82, 139.29, 128.56, 127.30, 125.83, 121.47, 121.19, 115.23, 113.76, 112.96,
112.05, 111.59, 111.38, 105.73, 65.40, 56.23, 56.18, 56.13, 55.92. ESI-MS calculated for
(C25H28N2O8S) [M-H]-: m/z 515; Molecular Weight (calculated from structure): 516.57.

HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.67 min,
purity: >95%.

4-chloro-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide

(12). Yield 55%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) δH 10.36 (s, 1H),
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9.00 (s, 1H), 8.00 (d, J= 8.5 Hz, 2H), 7.69 (s, 1H), 7.42 (d, J= 8.7 Hz, 2H), 7.40 (s, 1H),
7.22 (d, J= 8.6 Hz, 2H), 6.99 (d, J= 8.9 Hz, 1H), 6.88 (m, 1H), 5.09 (s, 2H), 3.79 (s, 3H),

3.73 (s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 164.86, 153.67, 153.07,

150.96, 138.88, 136.97, 133.96, 130.08, 128.96, 128.51, 125.80, 121.59, 115.19, 113.76,
112.96, 112.05, 105.74, 65.42, 56.24, 55.91. ESI-MS calculated for (C23H23ClN2O6S)

[M-H]-: m/z 489; Molecular Weight (calculated from structure): 490.96. HPLC mobile
phase: 80% ACN with 0.1% formic acid, retention time 0.67 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-nitrobenzamide (13).

Yield 42%, Yellow Powder. 1H NMR (400 MHz, DMSO-d6) δκ 10.36 (s, 1H), 9.04 (s,
1H), 8.40 (d, J= 8.8 Hz, 2H), 8.20 (d, J= 8.7 Hz, 2H), 7.69 (s, 1H), 7.45 (d, J= 10.4 Hz,
1H), 7.42 (s, 1H), 7.28 (d, J= 12.8 Hz, 1H), 6.99 (d, J= 8.9 Hz, 1H), 6.88 (m, 1H), 5.10 (s,

2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.89 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δC 164.31,

153.67, 153.02, 150.96, 149.68, 140.92, 138.52, 138.52, 129.67, 128.42, 125.76, 124.04,
122.01, 115.19, 113.76, 113.08, 112.05, 105.84, 65.47, 56.25, 55.91. ESI-MS calculated
for (C23H23N3O8S) [M-H]-: m/z 500; Molecular Weight (calculated from structure):

501.51. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.67 min,
purity: >95%.

3-cyano-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide

(14). Yield 44%, Pale Yellow Powder. 1H NMR (400 MHz, DMSO-d6) δκ 10.36 (s, 1H),
9.04 (s, 1H), 8.27 (s, 1H), 8.24 (d, J= 8.0 Hz, 1H), 8.09 (d, J= 7.7 Hz, 1H), 7.79 (dd, J= 2,

7.8 Hz, 1H), 7.67 (s, 1H), 7.43 (d, J= 10.4 Hz, 1H), 7.29 (d, J= 16.1 Hz, 1H), 7.28 (s, 1H),
6.99 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.10 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s,

3H); 13C NMR (100 MHz, DMSO-d6) δC 164.07, 153.69, 153.05, 150.96, 138.60, 136.27,
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135.53, 132.98, 131.72, 130.33, 128.47, 125.77, 121.89, 118.78, 115.18, 113.76, 112.98,
112.05, 112.01, 105.74, 65.46, 56.25, 55.92. ESI-MS calculated for (C24H23N3O6S) [Μ

Η]-: m/z 480; Molecular Weight (calculated from structure): 481.52. HPLC mobile phase:
80% ACN with 0.1% formic acid, retention time 0.67 min, purity: >95%.
3-bromo-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide

(15). Yield 24%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.36 (s, 1H),
9.04 (s, 1H), 8.15 (s, 1H), 7.97 (d, J= 7.9 Hz, 1H), 7.80 (d, J= 8.0 Hz, 1H), 7.67 (s, 1H),
7.52 (dd, J= 3, 7.9 Hz 1H), 7.29 (s, 1H), 7.25 (d, J= 8.5 Hz, 1H), 7.00 (d, J= 8.9 Hz, 1H),
6.87 (m, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz,

DMSO-d6) δc 164.38, 153.67, 153.03, 150.97, 138.67, 137.42, 134.84, 131.15, 130.67,

128.39, 127.33, 125.81, 122.15, 121.84, 115.21, 113.77, 113.01, 112.06, 105.81, 65.45,

56.24, 55.92. ESI-MS calculated for (C23H23BrN2O6S) [M-H]-: m/z 535; Molecular

Weight (calculated from structure): 535.41. HPLC mobile phase: 80% ACN with 0.1%
formic acid, retention time 0.67 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3-nitrobenzamide (16).

Yield 47%, Pale Yellow Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.63 (s, 1H), 9.04
(s, 1H), 8.80 (s, 1H), 8.46 (m, 2H), 7.86 (t, 1H), 7.68 (s, 1H), 7.45 (d, J= 6.6 Hz, 1H),

7.28 (m, 2H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s,
3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 163.78, 153.68, 150.97, 148.25,

138.50, 136.63, 134.65, 130.70, 128.41, 126.72, 125.78, 122.85, 122.00, 115.21, 113.78,
113.17, 112.07, 105.94, 65.49, 56.25, 55.92. ESI-MS calculated for (C23H23N3O8S) [M

H]-: m/z 500; Molecular Weight (calculated from structure): 501.51. HPLC mobile phase:
80% ACN with 0.1% formic acid, retention time 0.68 min, purity: >95%.
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4-bromo-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide

(17). Yield 40%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.37 (s, 1H),
9.01 (s, 1H), 7.91 (d, J= 8.5 Hz, 2H), 7.76 (d, J= 8.5 Hz, 2H), 7.68(s, 1H), 7.42 (d, J=
10.7 Hz, 1H), 7. 27 (s, 1H), 7.22 (d, J= 8.6 Hz, 1H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m,
1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6)
5c 164.98, 153.67, 153.06, 150.96, 138.87, 134.32, 131.90, 130.25, 128.51, 125.91,

125.79, 121.61, 115.19, 113.75, 112.96, 112.04, 105.74, 65.43, 56.24, 55.91. ESI-MS

calculated for (C23H23BrN2O6S) [M-H]-: m/z 535; Molecular Weight (calculated from
structure): 535.41. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time

0.68 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-2,4bis(trifluoromethyl)benzamide (18). Yield 31%, Pale Gray Powder. 1H NMR (400 MHz,

DMSO-d6) 5h 10.75 (s, 1H), 9.01 (s, 1H), 8.24 (m, 2H), 7.99 (d, J= 7.8 Hz, 1H), 7.67 (s,
1H), 7.57 (s, 1H), 7.26 (m, 3H), 6.99 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.78

(s, 3H), 3.73 (s, 3H), 2.89 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 164.65, 153.66,

153.18, 151.04, 140.14, 138.33, 131.10, 130.77, 130.57, 130.31, 128.66, 127.58, 127.26,
125.68, 124.96, 124.75, 123.94, 122.24, 122.10, 115.30, 113.89, 112.35, 112.08, 105.13,
65.47, 56.23, 55.91. ESI-MS calculated for (C25H22F6N2O6S) [M-H]-: m/z 591; Molecular

Weight (calculated from structure): 592.51. HPLC mobile phase: 80% ACN with 0.1%
formic acid, retention time 0.68 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-

(methylthio)benzamide (19). Yield 60%, Pale Gray Powder. 1H NMR (400 MHz,
DMSO-d6) δH 10.23 (s, 1H), 9.00 (s, 1H), 7.92 (d, J= 8.5 Hz, 2H), 7.70 (s, 1H), 7.41 (m,
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3H), 7.29 (s, 1H), 7.23 (d, J= 8.6 Hz, 1H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s,

2H), 3.80 (s, 3H), 3.73 (s, 3H), 2.87 (s, 3H), 2.55 (s, 3H); 13C NMR (100 MHz, DMSO-d6)
δc 165.33, 153.67, 153.10, 150.96, 143.72, 139.17, 131.10, 128.62, 128.56, 125.82,

125.37, 121.31, 115.20, 113.75, 112.89, 112.03, 105.67, 65.40, 56.23, 55.91, 14.60. ESI
MS calculated for (C24H26N2O6S2) [M-H]-: m/z 501; Molecular Weight (calculated from
structure): 502.60. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time
0.70 min, purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3-ethoxybenzamide

(20) . Yield 30%, White Powder. 1H NMR (400 MHz, DMSO-d6) δκ 10.26 (s, 1H), 9.00
(s, 1H), 7.72 (s, 1H), 7.44 (m, 4H), 7. 82 (s, 1H), 7.24 (d, J= 8.6 Hz, 1H), 7.15 (d, J= 8.1

Hz, 1H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m 1H), 5.08 (s, 2H), 4.12 (m, 2H), 3.79 (s, 3H),
3.73 (s, 3H), 2.87 (s, 3H), 1.37 (t, 3H); 13C NMR (100 MHz, DMSO-d6) δC 165.67,

158.93, 153.67, 150.98, 139.06, 136.60, 130.05, 128.51, 125.82, 120.22, 118.13, 115.23,
113.97, 113.77, 112.94, 112.05, 105.73, 65.41, 63.79, 56.24, 55.92, 15.08. ESI-MS

calculated for (C25H28N2O7S) [M-H]-: m/z 499; Molecular Weight (calculated from
structure): 500.57. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time

0.68 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3-methoxybenzamide

(21) . Yield 29%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) δκ 10.27 (s, 1H),
9.00 (s, 1H), 7.70 (s, 1H), 7.54 (d, J= 8.4 Hz, 1H), 7.44 (m, 3H), 7.29 (d, J= 2.9 Hz, 1H),
7.21 (d, J= 8.6 Hz, 1H), 7.18 (d, J= 8.1 Hz 1H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H),

5.08 (s, 2H), 3.85 (s, 3H), 3.79 (s, 3H), 3.73 (s, 3H), 2.87 (s, 3H); 13C NMR (100 MHz,
DMSO-d6) δC 165.69, 159.68, 153.67, 153.08, 150.97, 139.06, 136.66, 130.04, 128.53,
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125.81, 121.43, 120.29, 117.81, 115.23, 113.76, 113.45, 112.96, 112.04, 105.74, 65.41,

56.23, 55.91, 55.83. ESI-MS calculated for (C24H26N2O7S) [M-H]-: m/z 485; Molecular

Weight (calculated from structure): 486.54. HPLC mobile phase: 80% ACN with 0.1%
formic acid, retention time 0.68 min, purity: >95%.
3-chloro-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide

(22). Yield 20%, Gray Powder. 1H NMR (400 MHz, DVISO-Y) 5h 10.25 (s, 1H), 8.99 (s,
1H), 7.49 (m, 4H), 7.28 (d, J= 2.9 Hz, 1H), 7.23 (d, J= 8.6 Hz, 1H), 7.16 (m, 1H), 7.00 (d,

J= 8.9 Hz 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C

NMR (100 MHz, DMSO-d6) δo 164.47, 153.67, 153.03, 150.96, 137.23, 133.69, 131.95,

130.91, 128.41, 127.83, 126.96, 125.81, 115.19, 113.75, 113.00, 112.05, 105.79, 65.43,

56.24, 55.91. ESI-MS calculated for (C23H23ClN2θ6S) [M-H]-: m/z 489; Molecular

Weight (calculated from structure): 490.96. HPLC mobile phase: 80% ACN with 0.1%
formic acid, retention time 0.68 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-methyl-3-

nitrobenzamide (23). Yield 20%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.51
(s, 1H), 9.03 (s, 1H), 8.58 (s, 1H), 8.22 (d, J= 8.0 Hz 1H), 7.70 (m, 2H), 7.44 (d, J= 8.0

Hz 1H), 7.28 (m, 2H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.79 (s, 3H),
3.73 (s, 3H), 2.88 (s, 3H), 2.61 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δo 163.62,

153.68, 153.03, 150.96, 136.85, 134.13, 133.58, 132.59, 125.79, 123.99, 115.19, 113.77,
113.11, 112.06, 105.88, 65.46, 56.24, 55.92, 20.02. ESI-MS calculated for (C24H25N3O8S)

[M-H]-: m/z 514; Molecular Weight (calculated from structure): 515.54. HPLC mobile
phase: 80% ACN with 0.1% formic acid, retention time 0.70 min, purity: >95%.
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N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-

(trifluoromethyl)benzamide (24). Yield 39%, Pale Gray Powder. 1H NMR (400 MHz,
DMSO-d6) 5h 10.41 (s, 1H), 9.01 (s, 1H), 8.09 (d, J= 8.8 Hz, 1H), 7.68 (s, 1H), 7.54 (d,
J= 8.2 Hz, 1H), 7.42 (d, J= 8.6 Hz, 1H), 7.27 (m, 2H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m,
1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6)
5c 164.79, 153.68, 153.06, 150.99, 138.85, 134.41, 130.51, 128.45, 125.79, 121.65,

121.17, 115.22, 113.81, 112.96, 112.09, 105.76, 65.46, 56.26, 55.92. ESI-MS calculated
for (C24H23F3N2O6S) [M-H]-: m/z 539; Molecular Weight (calculated from structure):

524.51. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.72 min,
purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3-

(trifluoromethyl)benzamide (25). Yield 37%, White Powder. 1H NMR (400 MHz,
DMSO-d6) δH 10.51 (s, 1H), 9.03 (s, 1H), 8.28 (m, 2H), 7.98 (d, J= 7.7 Hz, 1H), 7.80 (m,
1H), 7.566 (s, 1H), 7.43 (d, J= 8.6 Hz, 1H), 7.28 (m, 2H), 7.00 (d, J= 8.9 Hz, 1H), 6.87

(m, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz,
DMSO-d6) δc 164.46, 153.68, 152.96, 150.97, 136.15, 132.29, 130.23, 129.83, 129.51,

128.67, 128.21, 125.83, 124.70, 124.66, 115.21, 113.78, 113.18, 112.07, 105.99, 65.48,

56.25, 55.92. ESI-MS calculated for (C24H23F3N2O6S) [M-H]-: m/z 523; Molecular

Weight (calculated from structure): 524.51. HPLC mobile phase: 80% ACN with 0.1%
formic acid, retention time 0.71 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-2-naphthamide

(26).

Yield 36%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) δH 10.50 (s, 1H), 9.02 (s, 1H),

8.59 (s, 1H), 8.09 (m, 4H), 7.75 (s, 1H), 7.65 (m, 2H), 7.50 (dd, J= 3, 6.6 Hz 1H), 7.29
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(m, 2H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.11 (s, 2H), 3.80 (s, 3H), 3.74 (s, 3H),
2.89 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 166.04, 153.68, 153.13, 150.99, 139.17,

134.78, 132.57, 132.54, 129.43, 128.52, 128.44, 128.37, 128.16, 127.37, 125.84, 124.68,
121.46, 115.23, 113.78, 112.94, 112.08, 105.73, 65.46, 56.26, 55.93. ESI-MS calculated
for (C27H26N2O6S) [M-H]-: m/z 505; Molecular Weight (calculated from structure):

506.57. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.68 min,
purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3,4,5trimethoxybenzamide (27). Yield 55%, White Powder. 1H NMR (400 MHz, DMSO-d6)
δH 10.17 (s, 1H), 8.97 (s, 1H), 7.68 (s, 1H), 7.35 (d, J= 8.2 Hz, 1H), 7.25 (m, 4H), 7.00 (d,

J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.89 (s, 6H), 3.79 (s, 3H), 3.73 (s, 6H), 2.88 (s,
3H); 13C NMR (100 MHz, DMSO-d6) δC 165.43, 153.65, 153.10, 151.02, 140.91, 138.91,

130.32, 128.36, 125.77, 121.55, 115.30, 113.85, 113.24, 112.11, 105.99, 105.83, 65.47,
60.63, 56.63, 56.25, 55.91. ESI-MS calculated for (C26H30N2O9S) [M-H]-: m/z 545;

Molecular Weight (calculated from structure): 546.59. HPLC mobile phase: 80% ACN
with 0.1% formic acid, retention time 0.70 min, purity: >95%.

3,4-dichloro-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide

(28). Yield 33%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) δκ 10.44 (s, 1H),
9.03 (s, 1H), 8.22 (d, J= 2.0 Hz, 1H), 7.96 (m, 1H), 7.85 (d, J= 8.4 Hz, 1H), 7.56 (d, J=

1.8 Hz, 1H), 7.40 (m, 1H), 7.25 (m, 2H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s,
2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δC 163.62,

153.67, 153.02, 150.98, 138.57, 135.52, 134.94, 131.79, 131.26, 130.03, 128.50, 128.41,
125.75, 121.83, 115.21, 113.80, 112.09, 105.84, 65.47, 56.25, 55.92. ESI-MS calculated
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for (C23H22CI2N2O6S) [M-H]-: m/z 523; Molecular Weight (calculated from structure):

525.40. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.71 min,
purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-methylbenzamide

(29). Yield 22%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.22 (s, 1H), 8.99 (s,
1H), 7.88 (d, J= 8.1 Hz, 2H), 7.71 (s, 1H), 7.43 (d, J= 8.6 Hz, 1H), 7.35 (d, J= 8.0 Hz,

2H), 7.28 (d, J= 3.0 Hz, 1H), 7.21 (d, J= 8.6 Hz, 1H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m,
1H), 5.08 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.87 (s, 3H), 2.40 (s, 3H); 13C NMR (100

MHz, DMSO-d6) 5c 165.81, 153.67, 153.08, 151.00, 142.18, 139.19, 132.36, 129.40,

128.48, 128.13, 125.83, 121.31, 115.24, 113.81, 112.90, 112.09, 105.72, 65.43, 56.25,

55.92, 21.48. ESI-MS calculated for (C2.∣I UVO-S [M-H]-: m/z 469; Molecular Weight
(calculated from structure): 470.54. HPLC mobile phase: 80% ACN with 0.1% formic
acid, retention time 0.72 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)hexanamide (30). Yield

55%, Yellow Powder. 1H NMR (400 MHz, DMSO-d6) 5h 9.94 (s, 1H), 8.93 (s, 1H), 7.53
(s, 1H), 7.25 (d, J=2.8 Hz, 1H), 7.15 (s, 2H), 6.99 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.04
(s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.84 (s, 3H), 2.29 (t, 2H), 1.59 (m, 2H), 1.29 (m, 4H),

0.88 (m, 3H); 13C NMR (100 MHz, DMSO-d6) δc 171.86, 153.66, 153.26, 150.98, 139.38,
128.82, 125.82, 120.66, 115.19, 113.78, 112.07, 111.61, 104.43, 65.35, 56.25, 55.91,
36.88, 31.34, 25.22, 22.35, 14.31. ESI-MS calculated for (C22H30N2O6S) [M-H]-: m/z 449;

Molecular Weight (calculated from structure): 450.55. HPLC mobile phase: 80% ACN
with 0.1% formic acid, retention time 0.68 min, purity: >95%.
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N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-[1,1'-biphenyl]-4-

carboxamide (31). Yield 36%, Gray Powder. 1H NMR (400 MHz, DMSO-^5) 5h 10.35 (s,
1H), 9.00 (s, 1H), 8.06 (d, J= 8.3 Hz, 2H), 7.86 (d, J= 8.3 Hz, 2H), 7.76 (m, 3H), 7.53 (m,

2H), 7.45 (m, 2H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.10 (s, 2H), 3.80 (s, 3H), 3.74
(s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 165.59, 153.69, 153.10, 151.00,

143.68, 139.56, 139.13, 134.01, 129.55, 128.82, 128.65, 128.50, 127.40, 127.07, 125.84,
115.24, 113.80, 112.92, 112.09, 105.73, 65.45, 56.26, 55.93. ESI-MS calculated for
(C29H28N2O6S) [M-H]-: m/z 531; Molecular Weight (calculated from structure): 532.61.

HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.69 min,
purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-3-methylbenzamide

(32). Yield 46%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.26 (s, 1H),
8.98 (s, 1H), 7.76 (m, 3H), 7.42 (m, 3H), 7.28 (s, 1H), 7.22 (d, J= 8.8 Hz, 1H), 6.99 (d,

J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C
NMR (100 MHz, DMSO-d6) δc 166.74, 153.46, 152.85, 151.21, 138.62, 138.54, 134.83,

132.98, 128.98, 128.35, 127.97, 125.55, 125.08, 121.53, 115.49, 114.12, 113.29, 112.34,
106.14, 65.54, 56.26, 55.85, 21.29. ESI-MS calculated for (CbJ bAzO-A) [M-H]-: m/z
469; Molecular Weight (calculated from structure): 470.54. HPLC mobile phase: 80%
ACN with 0.1% formic acid, retention time 0.71 min, purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-4-(trifluoromethoxy)

benzamide (33). Yield 38%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) δH 10.40
(s, 1H), 8.99 (s, 1H), 8.08 (d, J= 8.4 Hz, 2H), 7.69 (s, 1H), 7.55 (d, J= 8.2 Hz, 2H), 7.40

(d, J= 8.7 Hz, 1H), 7.27 (m, 2H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.79
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(s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δc 164.79, 153.68,

153.05, 150.99, 138.80, 134.41, 130.50, 128.41, 125.80, 121.72, 121.17, 119.18, 115.22,
113.81, 112.97,

112.09,

105.77, 65.46, 56.26, 55.92. ESI-MS calculated for

(C24H23F3N2O7S) [M-H]-: m/z 539; Molecular Weight (calculated from structure): 540.51.

HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time 0.77 min,
purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)-2-methylbenzamide

(34). Yield 23%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) δH 10.31 (s, 1H), 8.93 (s,
1H), 7.68 (s, 1H), 7.44 (m, 2H), 7.30 (m, 3H), 7.20 (d, J= 7.9 Hz, 1H), 7.00 (d, J= 8.6 Hz,
1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s, 3H); 13C NMR (100

MHz, DMSO-d6) δC 168.30, 153.66, 153.13, 151.04, 137.56, 135.69, 131.00, 128.43,

127.65, 126.09, 125.86, 115.31, 113.83, 112.30, 112.08, 105.19, 65.43, 56.25, 55.92,

19.77. ESI-MS calculated for (C24H26N2O6S) [M-H]-: m/z 469; Molecular Weight
(calculated from structure): 470.54. HPLC mobile phase: 80% ACN with 0.1% formic
acid, retention time 0.73 min, purity: >95%.
N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)thiophene-2-

carboxamide (35). Yield 53%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) δκ 10.27 (s,
1H), 8.98 (s, 1H), 8.02 (s, 1H), 7.88 (d, J= 4.6 Hz, 1H), 7.64 (s, 1H), 7.37 (d, J= 8.6 Hz,
1H), 7.25 (m, 3H), 7.00 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.80 (s, 3H), 3.74

(s, 3H), 2.88 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δC 160.34, 153.68, 150.98, 140.38,

138.52, 132.48, 129.63, 128.54, 128.40, 125.83, 121.74, 115.23, 113.80, 112.92, 112.06,
105.73, 65.45, 56.25, 55.92. ESI-MS calculated for (C21H22N2O6S2) [M-H]-: m/z 461;
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Molecular Weight (calculated from structure): 462.54. HPLC mobile phase: 80% ACN
with 0.1% formic acid, retention time 0.72 min, purity: >95%.

N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)isoxazole-5-

carboxamide (36). Yield 48%, Yellow Powder. 1H NMR (400 MHz, DMSO-d6) 5h 10.79
(s, 1H), 9.03 (s, 1H), 8.82 (s, 1H), 7.65 (s, 1H), 7.42 (d, J= 8.6 Hz, 1H), 7.26 (m, 3H),

7.00 (d, J= 8.6 Hz, 1H), 6.87 (m, 1H), 5.09 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.88 (s,

3H); 13C NMR (100 MHz, DMSO-d6) δo 162.90, 154.52, 153.64, 152.91, 152.33, 151.04,

137.40, 128.18, 125.65, 122.46, 115.28, 113.88, 113.38, 112.15, 107.32, 106.21, 65.55,

56.27, 55.90. ESI-MS calculated for (C20H21N3O7S) [M-H]-: m/z 446; Molecular Weight
(calculated from structure): 447.46. HPLC mobile phase: 80% ACN with 0.1% formic
acid, retention time 0.67 min, purity: >95%.
N1,N5-bis(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)glutaramide

(37). Yield 25%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 9.97 (s, 2H), 8.89 (s,
2H), 7.55 (s, 1H), 7.25 (s, 2H), 7.17 (s, 4H), 7.00 (d, J= 8.8 Hz, 2H), 6.89 (d, J= 8.6 Hz,
2H), 5.04 (s, 4H), 3.78 (s, 6H), 3.73 (s, 6H), 2.85 (s, 6H), 2.38 (m, 4), 1.91 (m, 2); 13C

NMR (100 MHz, DMSO-d6) δo 171.37, 153.66, 153.25, 150.97, 139.33, 128.79, 125.81,

120.73, 115.19, 113.78, 112.07, 111.66, 104.47, 65.37, 56.25, 55.91, 36.06, 21.31. ESI
MS calculated for (C37H44N4O12S2) [M-H]-: m/z 799; Molecular Weight (calculated from
structure): 800.90. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time
0.70 min, purity: >95%.

2,2'-oxybis(N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)acetamide)

(38) . Yield 18%, Gray Powder. 1H NMR (400 MHz, DMSO-d6) δH 9.77 (s, 2H), 8.84 (s,
2H), 7.39 (s, 2H), 7.23 (s, 2H), 7.14 (s, 2H), 7.00 (m, 4H), 6.88 (s, 2H), 5.04 (s, 4H), 3.78
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(s, 6H), 3.72 (s, 6H), 3.67 (s, 4H), 3.59 (s, 4H), 2.85 (s, 3H); 13C NMR (100 MHz,

DMSO-d6) δc 168.55, 153.64, 153.11, 150.96, 125.76, 115.19, 113.76, 112.31, 112.03,

71.28, 65.40, 56.22, 55.89. ESI-MS calculated for (C36H42N4O13S2) [M-H]-: m/z 801;

Molecular Weight (calculated from structure): 802.87. HPLC mobile phase: 80% ACN
with 0.1% formic acid, retention time 0.68 min, purity: >95%.
ethane-1,2-diyl

bis((3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)

carbamate) (39). Yield 24%, Pale Gray Powder. 1H NMR (400 MHz, DMSO-d6) 5h 9.80

(s, 2H), 8.86 (s, 2H), 7.39 (s, 2H), 7.22 (s, 2H), 7.15 (d, J= 7.5 Hz, 2H), 7.03 (m, 4H),

6.87 (s, 2H), 5.04 (s, 4H), 4.35 (s, 3H), 3.78 (s, 6H), 3.72 (s, 6H), 2.85 (s, 6H), 2.51 (s,

6H); 13C NMR (100 MHz, DMSO-d6) δc 153.73, 153.61, 153.46, 151.05, 139.05, 129.01,

125.71, 120.36, 115.31, 113.86, 112.09, 110.93, 103.81, 65.34, 63.20, 56.24, 55.89. ESI
MS calculated for (C36H42N4O14S2) [M-H]-: m/z 817; Molecular Weight (calculated from
structure): 818.87. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention time

0.65 min, purity: >95%.
(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl)bis((3-((2,5-dimethoxybenzyl)oxy)-4-

(methylsulfonamido)phenyl)carbamate) (40). Yield 19%, Pale Gray Powder. 1H NMR
(400 MHz, DMSO-d6) 5h 9.77 (s, 2H), 8.85 (s, 2H), 7.38 (s, 2H), 7.23 (s, 2H), 7.15 (d, J=

7.9 Hz, 2H), 7.00 (m, 4H), 6.87 (m, 2H), 5.03 (s, 4H), 4.21 (s, 4H), 3.77 (s, 6H), 3.72 (s,
6H), 3.67 (s, 4H), 3.59 (s, 4H), 2.84 (s, 6H); 13C NMR (100 MHz, DMSO-d6) δc 153.87,

153.64, 153.49, 151.04, 139.20, 129.04, 125.76, 120.27, 115.31, 113.84, 112.08, 110.82,
103.71, 70.20, 69.16, 65.34, 64.07, 56.24, 55.90. ESI-MS calculated for (C40H50N4O16S2)

[M-H]-: m/z 905; Molecular Weight (calculated from structure): 906.97. HPLC mobile
phase: 80% ACN with 0.1% formic acid, retention time 0.68 min, purity: >95%.
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4-amino-N-(3-((2,5-dimethoxybenzyl)oxy)-4-(methylsulfonamido)phenyl)benzamide

(41). Yield 60%, Pale Yellow Powder. 1H NMR (400 MHz, DMSO-^5) 5h 9.82 (s, 1H),
8.92 (s, 1H), 7.72 (d, J= 8.7 Hz, 3H), 7.41 (d, J= 8.6 Hz, 1H), 7.29 (d, J= 2.8 Hz, 1H),
7.17 (d, J= 8.5 Hz, 1H), 6.99 (d, J= 8.9 Hz, 1H), 6.87 (m, 1H), 6.60 (d, J= 8.5 Hz, 2H),

5.78 (s, 2H), 5.07 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 2.86 (s, 3H); 13C NMR (100 MHz,
DMSO-d6) 5c 165.75, 153.67, 153.19, 152.72, 150.95, 139.94, 129.63, 128.70, 125.90,

121.37, 120.54, 115.21, 113.71, 113.03, 112.57, 112.01, 105.36, 65.35, 56.21, 55.90.

ESI-MS calculated for (C23H25N3O6S) [M-H]-: m/z 470; Molecular Weight (calculated
from structure): 471.53. HPLC mobile phase: 80% ACN with 0.1% formic acid, retention
time 0.65 min, purity: >95%.

4,4,-((2,2,-oxybis(acetyl))bis(azanediyl))bis(N-(3-((2,5-dimethoxybenzyl)oxy)-4-

(methylsulfonamido)phenyl)benzamide) (42). Yield 60%, Gray Powder. 1H NMR (400

MHz, DMSO-d6) 5h 10.36 (s, 1H), 10.20 (s, 1H), 8.98 (s, 2H), 7.99 (d, J= 8.6 Hz, 3H),
7.84 (d, J= 8.6 Hz, 3H), 7.70 (m, 2H), 7.42 (d, J= 8.8 Hz, 2H), 7.22 (d, J= 8.6 Hz, 2H),
7.00 (d, J= 8.9 Hz, 2H), 6.87 (m, 2H), 5.09 (s, 4H), 4.35 (s, 3H), 3.79 (s, 6H), 3.73 (s,

6H), 2.88 (s, 6H); 13C NMR (100 MHz, DMSO-d6) δc 169.07, 165.31, 153.68, 153.08,

150.98, 141.84, 130.06, 129.10, 125.86, 119.35, 115.23, 113.78, 112.90, 112.08, 105.73,

89.07, 71.35, 65.44, 56.25, 55.92. ESI-MS calculated for (C50H52N6O15S2) [M-H]-: m/z
1039; Molecular Weight (calculated from structure): 1041.11. HPLC mobile phase: 80%
ACN with 0.1% formic acid, retention time 0.65 min, purity: >95%.
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5.2.3. Cell culture

T98G, A172, U87 and U251 cells were from ATCC. The cells were maintained in

RPMI1640 or DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL
penicillin and 100 mg/mL streptomycin in a humidified incubator with 5% CO2 at 37 °C.

5.2.4. Cell viability analysis

MTT assay was used to evaluate the effect of HSP27 inhibitors on the growth of
T98G, A172, U87 and U251 cells in eight replications. 3000 cells per well were seeded
with RPMI1640 or DMEM in 96-well flat-bottomed plates for 24 h and were then
exposed to various concentrations of test compounds dissolved into DMSO (highest final

concentration 0.1%) in the medium for 48 h. controls received DMSO at a same
concentration as that in highest does drug-treated cells. Cells were incubated in 100 μL 1
mg/mL of MTT reagent diluted in fresh media at 37 °C for 2 h. Supernatants were
removed from the wells, and the precipitated MTT dye was dissolved in 200 μL∕well
DMSO. Absorbance at 570 nm was determined on a SpectraMax Plus 384

spectrophotometer (Molecular Devices).

5.2.5. Experimental animals

Male C57BL∕6 mice and nude mice were purchased from Taconic lab. Mice were
housed in Plexiglas cages, kept on a 12/12 -h light-dark cycle, and received food and
water ad libitum in a temperature- and humidity- controlled environment. All the
experimental procedures involving animals were performed in accordance with the guide
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for the Care and Use of The Cleveland State University (CSU) Institutional Animal Care
and Use Committee (IACUC).

5.2.6. Maximum Tolerated Dose (MTD) study

12 C57BL/6 mice were randomly divided into three groups. Mice were injected
with vehicle (DMSO) or compounds (100 mg/kg in PBS) by intraperitoneal injection (IP)

daily. Mice would be euthanized after 10 days treatment. Body weights were determined

at the start dosing day and the end dosing day.
Hematology analysis. Non-fasted blood samples were collected from the heart

immediately for hematology analysis after the euthanizing. Hematology analysis was
performed with a hematology analyzer—Element HT5 (Heska Corporation, USA).

Hematoxylin and eosin (H&E) staining. Five tissues (Heart, liver, spleen, lung,

kidney) were collected. Then, the tissues are fixed in 10% neutral buffered formalin (10
mL of formalin per cm3 tissue). Tissues are cut and transferred into cassettes. Tissues
were immersed into increasing concentration ethanol to remove the water and formalin
(dehydration), then, using xylene was used to remove alcohol and allow infiltration with

paraffin wax. Then, tissues were embedded into paraffin wax. Tissues were cut at 4 μm

by microtome (sectioning). Generally, tissue slides are transparent when unstained. H&E
staining would be thus used to provide contrast to tissue sections, leading tissue structures

more visible and easier to evaluate. The protocol was slightly modified from Wang’s
method 28.
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5.2.7. Western blotting

Cells were cultured in 6-well culture plates and incubated with DMSO or inhibitors

and then lysed with RIPA supplemented with a protease inhibitor cocktail. After

incubating the cells on ice for 10 min, lysates were collected into a 1.5 mL centrifuge

tube, then, the supernatant would be collected after centrifuged at 10,000 g for 10 min.
Protein concentrations were determined by the BCA Protein Assay kit. Fifty micrograms

of total protein lysate for each sample were boiled with 1x loading buffer for 10 min.
Samples were then separated on a 10% SDS-polyacrylamide gel and transferred to
polyvinylidene fluoride (PVDF) membrane. The membrane was blocked for 2 h with 5%
non-fat milk in 1x TBS-T (150 mM NaCl, 10 mM Tris, pH7.4, 0.1% Tween 20) at room
temperature and then incubated with primary antibody at 4°C overnight. After the

membrane was incubated with the primary antibody and washed three times with 1x
TBS-T for 10 min each wash, it was incubated with the secondary antibody for 60 min at

room temperature. The membrane was washed three times again for 10 min each time

with 1x TBS-T. Eventually, the membranes were incubated with SuperSignal West Pico

Chemiluminescent Substrate (Pierce) according to the protocol of the manufacturer.

5.2.8. HSP27 chaperone activity assay

24 μL 1 mg/mL insulin stock solution was added to the single well of 384 well

plate, 3 μL 5 mg/mL α -crystallin (a segment of HSP27 responsible for the chaperone

function of HSP27), 71 μL PBS with three different concentrations (10, 100 and 1000
nM) of compounds dissolved inside were added as well. The mixture was thoroughly

mixed and incubated at 37 °C for 5 min, then 2 μL of 1 M DTT in water was added to
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initiate the insulin aggregation. The mixture of insulin in the absence or presence of α-

crystallin with 0.1% DMSO was used as control. The absorbance at 400 nm was
monitored every three minutes continuously for 2 h using Molecular Devices SpectraMax
Microplate reader.

5.2.9. Immunofluorescence assay

U87 and T98G cells were seeded in 6-well plates. Cover slips were placed into the

wells and the cells could attach naturally. After 24 h, cells were treated with compounds
4 and 26 at 50 nM for 12 h, respectively. Then, cells were washed with PBS and fixed
with 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 10 min,

blocked with 1% bovine serum albumin for 30 min. Several washing steps with PBS

occurred in between fixation, permeabilization and blocking. Then, incubation with the
AR primary antibody for 1 h. Followed by washing with PBS then fluorescein-labeled
secondary antibodies for 1 h. DAPI (1 μg∕mL) was incubated for 10 min to stain the

nucleus. Images were visualized and analyzed using Echo Revolve Microscope.

5.2.10. In vivo xenograft study

U87 cells were re-suspended in sterile PBS (100 μL) and injected (5×106

cells/injection) subcutaneously at the left and right flank of a male nude mouse (5-6
weeks, n = 4/group, 2 tumors per mouse and 8 tumors per group). Tumors and body

weight were monitored with Vernier calipers three times weekly, and tumor volume was

calculated by the following formula: V= 2/3 d1×d22, where d1 is the larger diameter and
d2 is the smaller diameter. When the tumor volume reached approximately 50 mm3, mice
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were injected with vehicle (DMSO) or compound 4 or 26 (20 mg/kg in PBS) by

intraperitoneal injection (IP) three times weekly for 14 days, and the tumor size were
monitored and measured at the same time. In the end, mice were euthanized by exposure
to excess CO2 and the tumors were removed, weighted. And every two tumors from

every single one mouse was mixed and homogenized with RIPA buffer (Protein
inhibitors and PMSF were added) to prepare the tumor lysates after tumor were weighted.

5.2.11. Determination of anti-glioblastoma agents in mouse plasma and brain

HPLC-MS/MS conditions: The HPLC-MS/MS method was performed with a

Shimadzu UPLC system (Columbia, MD) which consisted of a Prominence DGU-20A3r

inline degasser, two LC-30 AD pumps, a SIL-30 AC autosampler and a CBM-20A

controller. The chromatographic separation was performed on a Kinetex C18 column (50
mm × 2.1 mm, 1.3 μm) with a mobile phase consisting of acetonitrile-0.1% formic acid
and water (50:50, v/v) at a flow rate of 0.3 mL/min. The temperature of the column was

maintained at 36°C. The injection volume was 5.0 μL. Mass spectrometric detection was
operated on an AB Sciex Qtrap 5500 mass spectrometer (Toronto, Canada) with negative

electrospray ionization mode. The multiple reaction monitoring (MRM) function was
used for quantification with the transitions of compound 4, 26 and IS compound I, which

were detected at m/z 501.2→ 151.1, m/z 507.2→ 151.1 and m/z 487.1→151.1, respectively

(product ion spectrums showed in supplemental material). The optimized ion source
parameters were set as follows: ion spray voltage, 2000 V; ion sourse temperature, 550°C;
nebulization gas 40 psi; auxiliary gas, 40 psi; curtain gas, 30 psi. Compound parameters
were as follows: compound 4: declustering potential, 40V; entrance potential, 5V;
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collision energy, 23V; Collision entrance potential, 15V. compound 26: declustering

potential, 40V; entrance potential, 5V; collision energy, 25V; Collision entrance potential,

15V. compound I (Internal standard): declustering potential, 35V; entrance potential, 5V;
collision energy, 30V; Collision entrance potential, 15V. Preparation of standards and

samples. The stock solutions were prepared by dissolving compound 4, 26 and compound

I in methanol at 1.0 mg/mL. Then, the stock solution of compound 4 or 26 was serially
diluted with methanol into a concentration gradient: 1.0, 2.0, 5.0, 10, 20, 50, 100, 200,

500, 1000 ng/mL. Also, a 500 ng/mL working solution of compound I (IS) was prepared

in methanol from the stock solution. All the solutions were stored at 4°C in the dark. A
simple protein precipitation method was applied to extract compound 4 or 26 from mouse
plasma or brain homogenate (0.4 g brain tissue mix with 2 mL PBS). Briefly, 100 μL of
each sample, 40 μL of compound I (IS, 500 ng/mL), and 800 μL of methanol were
combined in a 1.5 mL tube. Then, it was vortexed and centrifuged at 12,000 g for 5 min.

The supernatant was collected and then transferred into a new 1.5 mL tube. The liquid

was dried by a nitrogen blowing instrument. The residue was stored at -80 °C and

dissolved with 100 μL 50% acetonitrile before analysis.

5.2.12. Statistical analysis

Statistical and graphical information was determined using GraphPad Prism
software (GraphPad Software Incorporated) and Microsoft Excel (Microsoft Corporation).
Gray values from western blot were determined via Quantity One Software (Bio-Rad).

The determination of IC50s was performed using nonlinear regression analysis.
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Statistically significant differences were calculated with the two-tailed unpaired Student’s

t-test andp values reported at 95% confidence intervals.
5.3. Results and discussions

5.3.1. Lead optimization and summarization of the structure-activity relationship

(SAR)

Our previous study identified compound I (shown in Figure 19. N-(3-((2,5dimethoxybenzyl)oxy)-4-(methylsulfonamido) phenyl)-4-methoxybenzamide), as a dual
tubulin and HSP27 inhibitor, having potent anti-glioblastoma activity in vitro and in vivo

29. Compound I displayed potent antiproliferative activity against four different GBM

cells in the range of 1-10 nM, also significantly shrunk the GBM tumor size in nude mice
xenograft model at 20 mg/kg. In the current study, a total of 42 new derivatives and
dimers based on compound I were synthesized by modifying the circled moietie in

Figure 19. We have explored different structures at R1 domain, including aromatic rings
and aliphatic groups.

Figure 19. Core structure of the new derivatives.
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In this project, 42 different new derivatives were synthesized. The synthesis is
illustrated in Scheme 1.

Scheme 1. Synthesis of compounds 1-42. Reagents and conditions: (a) 2, 5dimethoxybenzyl chloride, DMF, K2CO3; (b) Methanesulfonyl chloride, NaH, DMF; (c)
NH4Cl, Zn, H2O, THF; (d)R1COCl, K2CO3, DMF; (e) R2C2O2Cl2, DMF, K2CO3; (f)
NH4Cl, Zn, H2O, THF; (g) R3C2O2Cl2, DMF, K2CO3.

All of these new compounds were examined for potency on the growth inhibition
of four different GBM cells including A172, U87, T98G and U251cells, and AR

downregulation effect in T98G cells. The results are summarized in Table 7 and Figure
20. In Table 7, the results showed that compounds 4, 5, 6, 8, 11, 12, 17, 19, 25, 26 and 29

have the IC50s lower than 1 μM in all the GBM cells. Meanwhile, compounds 4, 13, 15,

19, 26, 33, 34, 35, 36 and 37 showed significant AR downregulation activity at 100 nM
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in T98G cells. To refine the screening results, compounds dose was decreased to 50 nM
to determine AR downregulation activity in T98G cells. The results showed in Figure 21,

indicated that compounds 4 and 26 have potent AR downregulation activity at 50 nM in
T98G cells, similar to compound I. Also, the IC50s of compounds 4, 8, 19 and 26 is lower

than 0.1 μM in all the GBM cells. With the crosstalk of the IC50s and AR downregulation

activity of these new compounds, both compounds 4 and 26 have potent AR

downregulation activity and low IC50s in the GBMs. Thus, compounds 4 and 26 were
identified, which have similar activity to compound I, potentially targeting HSP27 to

induce AR degradation in GBM.
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Figure 20. AR downregulation effect of compounds 1-42 at 100 nM for 12 h in T98G
cells. The proteins were analyzed by western blotting with specific antibodies and the
results are representative images and quantification. Data are expressed as Mean ± SD
(n=3).
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Figure 21. AR downregulation effect of promising compounds at 50 nM for 12 h in T98G
cells. The proteins were analyzed by western blotting with specific antibodies and the
results are representative images and quantification. Data are expressed as Mean ± SD
(n=3).
5.3.2. Compounds 4 and 26 inhibit the chaperone activity of HSP27

The lead compound, compound I was identified to bind to HSP27 from our
previous study 29. Thus, the chaperone activity of HSP27 of the derivates, compounds 4

and 26 was determined. It is well confirmed that HSP27 is critical for stabilizing its client

proteins, including AR 60,64,65. The cellular protective function of HSP27 is regulated by
the chaperone activity and preventing cell death from stress stimulation. To determine the

in vitro chaperone activity, insulin is often used as a model substrate protein to mimic the
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protein aggregation and HSP27 serves as the chaperone to prevent aggregation. In the
current study, dithiothreitol (DTT) could denature insulin, which induces insulin B chain
aggregation. α-crystalline is the chaperone function domain of HSP27, which was used in
this study to perform the chaperone assay. In the presence of the chaperone protein,

insulin aggregation level could be decreased, because the stable complex was formed by
HSP27 and unfolded insulin B chain

54.

The aggregated insulin could be determined by

the absorbance at 400 nm. The capability of compounds 4 and 26 to modulate the in vitro
chaperone activity of HSP27 was evaluated by monitoring the DTT induced insulin

aggregation in the presence of α-crystalline with or without compounds 4 and 26. The
results showed in Figure 22, α-crystalline exhibits significant potency against DTTinduced insulin aggregation. Compounds 4 and 26 do not interfere with DTT-induced
insulin aggregation, while the chaperone activity of α-crystalline was inhibited with the
presence of compound 4 or 26. The results indicated that the inhibitory activity of
compounds 4 and 26 to the in vitro chaperone function of HSP27.

Figure 22. Inhibition of Compounds 4 and 26 chaperone function. α-crystallin lost the
activity to prevent DTT-induced insulin B chain aggregation in the presence of
compound 4 or 26. The kinetics of the DTT-induced insulin B chain aggregation was
monitored in the absence of a chaperone protein or in the presence of a chaperone protein
with or without compound 4 or 26. The mixture of insulin and DTT with or without other
components with the assay buffer was incubated for 80 min at 37°C, and the absorbance
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at 400 nm was measured. The compound at this concentration or below did not interfere
with DTT and insulin interaction. The results are representative of three independent
experiments, each curve was measured in triplicate, and the mean was used to generate
the curve. The representative one of the three experiments is presented. The statistical
analysis was performed for the end reading of the curve with the unpaired /-test, **p<0.01,
with compound 4 or 26 versus without compound 4 or 26.
5.3.3. Compounds 4 and 26 dose-dependently decrease AR and mutated AR protein

levels in GBM cells

It is well established that AR is one of the most common client proteins of HSP27
and AR degradation induced by knocking down HSP27 has been reported in prostate

cancer 73. Our hypothesis is eliminating AR via inhibiting HSP27 by a small molecule
with potential to cross the BBB, which is vital for GBM treatment. The results showed in

Figure 23 showed that Compounds 4 and 26 downregulate AR protein level in GBM

cells dose-dependently. Both compounds 4 and 26 could significantly downregulate AR

protein level at 25, 50 and 100 nM in T98G and U87 cells. Moreover, compounds 4 and
26 also could downregulate mutated AR (AR-V7) in T98G cells, since AR-V7 was not

detected in U87 cells. The results demonstrated that the advantage to targeting AR

compared with AR antagonists, since both wild type and mutated AR could be down
regulated by the compounds. So far, compounds 4 and 26, as small-molecule HSP27
inhibitors, could inhibit GBM cell proliferation potently and downregulate AR protein

level.
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Figure 23. AR and or mutated AR (AR-V7) was abolished with compound 4 or 26
treatment in T98G cells and U87 cells. AR and AR-V7 expressions were analyzed by
western blotting after the compound treatment. The experiment was repeated three times
independently, and the representative image and quantification are shown. Data are
expressed as Mean ± SD (n=3). *p< 0.05, **p<0.01 compared to the DMSO treatment
group by the unpaired t-test.

5.3.4. AR downregulation effect of compounds 4 and 26 was confirmed with

immunofluorescence imaging

We also examined the AR distribution in U87 cells and T98G cells after the

treatment with both compounds 4 and 26, respectively. Immunofluorescence imaging was
used to visualize the AR protein in living cells. The results showed that the fluorescence

intensities of AR were decreased with the treatment of compounds 4 and 26 in both cell
lines compared to DMSO group (Figure 24), which is consistent to the western blotting

results. Furthermore, AR was eliminated in nucleus in T98G cells with compounds 4 and
26 treatment, which indicating that HSP27 chaperone activity was suppressed to escort

the client protein AR translocated into nucleus.
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Figure 24. Expression and location of AR with DMSO or compounds treatment in T98G
cells and U87 cells. The cells were analyzed by the immunofluorescence assay.
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5.3.5. Compounds 4 and 26 significantly shrunk the GBM growth and AR level in

the xenograft tumor model

The in vivo activity with GBM model test is necessary to be a potential drug
candidate, compounds 4 and 26, as HSP27 inhibitors, bear potent in vitro anti-GBM
activities. In this study, the xenograft tumor model was developed by subcutaneously
injecting U87 cells into the left and right flank of nude mice. Compounds 4 and 26 were

administrated into the nude mice with intraperitoneal injection (IP) every two days for 2
weeks, once the tumor size reach to 150 mm3. The mice body weight and tumor size were

measured and recorded. As shown in Figure 25, nude mice body weight was not affected
with compound 4 or 26 administration. The results were consistent with the in vivo

toxicity study (Figure 25B). The tumor images were lined up in Figure 25 A, the tumor
size was subjectively considered decreased. The tumor size was also measured during

treatment and the measurements showed significant decrease in tumor size in both
compounds 4 and 26, compared with DMSO group in Figure 25C. Tumor weight results

showed in Figure 25D, showed compounds 4 and 26 group significantly decreased the

tumor weight compared with DMSO group. To confirm that GBM tumor inhibition effect

was from AR suppression. The AR expression level in tumor was examined via western
blot (Figure 25E), AR protein level was decreased in both compounds 4 and 26 groups,

compared with DMSO group. The results indicated that both compounds 4 and 26 exhibit
potent in vivo activity, providing the solid evidence that compounds 4 and 26 could be

promising new drug candidates to treat AR overexpressed GBM.
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Figure 25. In vivo efficacy of compound 4 and 26 in human GBM. A total of 5× 106 U87
cells were inoculated subcutaneously into nude mice, which were randomly assigned to
DMSO and the compounds treated groups. Nude mice were treated with compound 4 or
26 at 20 mg/kg with IP injection. Tumor images (A, n=8); Body weight (B, n=4); Tumor
size (C, n=8, data are expressed as Mean ± SD, compound 4 *p<0.05, compound 26
#p<0.05 compared to DMSO group); tumor weight (D, n=8, data are expressed as Mean ±
SD, compound 4 *p<0.05, compound 26 #p<0.05 compared to DMSO group) and AR
expression in tumor was analyzed by western blotting, as shown by representative images
and by quantification (E, n=4, data are expressed as Mean ± SD, compound 4 **p<0.01,
compound 26 ##p<0.01 compared to DMSO group )
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5.3.6. Compounds 4 and 26 could cross blood brain barrier

Since compounds 4 and 26 could inhibit GBM tumor growth in mice xenograft

model, and do not cause toxicity to mice, compounds 4 and 26 could be the potential drug
candidates to treat GBM. However, whether the candidates could cross blood brain

barrier is a critical factor to consider for the treatment of GBM. Thus, the determination
of compounds 4 and 26 in mouse plasma and brain with HPLC-MS/MS was applied. The

mouse plasma and brain concentrations of compounds 4 and 26 at different time are

exhibited in Figure 26. The pharmacokinetic parameters are listed as Mean ± SD in
Table 8. The results showed that compounds 4 and 26 were rapidly absorbed and

distributed. The apparent elimination half-life (t1/2) of compounds 4 and 26 were 5.25 h
and 6.28 h, respectively, indicating both of compounds 4 and 26 could be cleared fast

from the mouse plasma. Moreover, AUC of compound 4 in mouse plasma reached to
32.13 μghmL. Moreover, the compound 4 was detected in brain tissue after IP
administration, the AUC of compound 4 in brain tissue is 0.62 μgh∕g (2% of the

concentration in blood), indicating that compound 4 in the blood circulation was able to
pass the blood-brain barrier (BBB) and accumulate in the brain tissue (Figure 26A & B).
AUC of compound 26 in mouse plasma reached to 80.84 ugh/mL. Moreover, the
compound 26 was detected in brain tissue after IP administration, the AUC of compound

26 in brain tissue is 2.44 μgh∕g (3% of the concentration in blood), indicating that
compound 26 in the blood circulation was able to pass the blood-brain barrier (BBB) and

accumulate in the brain tissue (Figure 26C & D). compared with the lead compound,
compound I from our previous study 74, compounds 4 and 26 have slightly increased

BBB permeability.
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Figure 26. Plasma and brain tissue concentration-time profiles of compound 4 (A and B)
and 26 (C and D) with IP administration in mice. (Mean ± SD, n=4)

Table 8. Non-compartmental pharmacokinetic parameters of compounds 4 and 26 in
mouse after IP administration (n=4, Mean ± SD).
Pharmacokinetic
Values
Plasma
Brain
parameters
Compound 4
5.25±1.57 (h)
6.06±2.00 (h)
t1/2
Cmax

20.20±8.10 (μgZmL)

0.68±0. 25 (μgZg)

AUC0-24h

20.02±5.62 (μg.hZmL)

0.31±0.05 (μg.hZg)

AUC0-∞h

32.13±5.59 (μg.hZmL)

0.62±0.24 (μg.hZg)

Compound 26
t1/2

6.28±1.39 (h)

8.66±3.81 (h)

Cmax

30.62±6,99 (μgZmL)

0.76±0.19 (μgZg)

AUC0-24h

61.92±15.47 (μg.hZmL)

1.34±0.31 (μg.hZg)

AUC0-∞h

80.84±12.78 (μg.hZmL)

2.44±0.53 (μg.hZg)
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5.3.7. Compounds 4 and 26 do not show in vivo toxicity with high dose exposure

To further confirm these two promising compounds 4 and 26 could be the drug

candidates, the in vivo toxicity is necessary to determine. In this study, C57BL/6 mice
were exposed to the compounds 4 and 26, respectively, at 100 mg/kg per day for 10 days
to evaluate the toxicity. Mice condition observation, body weight, tissue staining and

hematology in mice were determined to demonstrate the toxicity of compounds 4 and 26.
(1) Condition observation: all of the groups of mice did not show any syndromes of
toxicity, such as dehydration, acute pain or distress. (2) Body weight: the mice body

weight was monitored and recorded every day before dosing, the results showed in
Figure 27A, there is no growth rate difference between compounds 4 and 26 groups with
DMSO group in 10 days. (3) Hematology. The results showed in Table 9. There is no

significant changed compared with DMSO group. (4) Tissue staining. At the end of the

day, the mice were sacrificed, then the tissues (kidney, spleen, lung, liver and heart) were
collected and rinsed with PBS, then, fixed with 4% formalin for 24 h at room temperature.

After tissues were sliced and stained with Hematoxylin and Eosin. The images were
taken from the microscope, the results showed in Figure 27B. The results showed that

compared with DMSO group, there is no severe injuries observed in compounds 4 and 26
groups in kidney, spleen, lung, liver and heart tissues. In kidney, normal histology of the
glomerulus and tubules was found and there is no necrosis and glomerular atrophy and

other inflammatory changes in drug treatment groups; In spleen, it showed that intact and
distinct spleen follicle with clear white pulp, red pulp and marginal zone in all the DMSO
and drug treatment groups; In lung, there is no severe injury or fibrosis observed in all the

groups; In liver, all these groups showed normal hepatic architecture with central vein
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and surrounding hepatocytes, sinusoids and nucleus; In heart, there is no obvious infarcts,

inflammatory cell infiltration, rupture or necrosis of myocardial cells. Overall, there is no
abnormal physical condition observed in compounds 4 and 26 treatment group, the body

weight growth rate in drug treatment groups also similar to DMSO group and there is no
obvious tissue damage in various tissue pathology slides observed in both compounds 4
and 26 groups, which indicating compounds 4 and 26 do not cause acute toxicity in mice.
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Figure 27. Body weight (A) and microscope images of the kidney, spleen, lung, liver and
heart stained with H&E staining after compounds 4 or 26 treatment (B). Data expressed
with Mean ± SD (n=3).
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Table 9. Comparative hematology (Mean ± SD) between different groups.
Parameters

Reference

Groups
DMSO

4

26

Range

WBC (10^3∕μL)

9.69±1.48

10.83±1.58

11.18±2.07 ↑

0.80-10.6

Neu (10^3∕μL)

1.24±0.40

2.40±0.76

2.57±0.77

0.23-3.60

Lym (10^3∕μL)

7.63±1.06

7.68±0.97

7.84±1.20

0.60-8.90

Mon (10^3∕μL)

0.62±0.45

0.5530.24

0.56±0.20

0.04-1.40

Eos (10^3∕μL)

0.12±0.07

0.143±0.12

0.12±0.03

0.00-0.51

Bas (10^3∕μL)

0.09±0.06

0.06±0.02

0.09±0.04

0.00-0.12

Neu (%)

12.70±2.95

21.95±5.08

22.70±3.81

6.50-50.0

Lym (%)

79.14±7.36

71.33±6.89

70.60±4.65

40.0-92.0

Mon (%)

6.14±4.17

5.00±1.57

4.92±1.03

0.90-18.0

Eos (%)

1.14±0.55

1.23±0.88

1.04±0.21

0.00-7.50

Bas (%)

0.88±0.53

0.50±0.16

0.74±0.23

0.00-1.50

RBC (10^6∕μL)

12.21±0.54 ↑

10.47±0.18

11.46±0.52

6.80-12.00

HGB (g∕dL)

15.62±0.58

13.83±0.36

15.34±0.45

10.5-19.0

HCT (%)

59.36±1.28 ↑

52.03±0.73

55.16±2.15

37.2-58.0

MCV (fL)

48.68±1.28

49.73±0.34

48.20±2.48

42.6-55.6

MCH (pg)

12.78±0.16 ↓

13.23±0.17

13.40±0.42

13.0-19.8

MCHC (g∕dL)

26.34±0.69

26.65±0.37

27.80±0.66

26.0-37.9

RDW-CV (%)

16.74±0.48

16.30±0.36

17.14±0.92

11.1-21.1

PLT (10^3∕μL)

1510.6±451.2

1940.75±155.9

1461.8±425.5

565-1849

MPV (fL)

4.88±0.13

4.75±0.06

4.98±0.20

3.6-6.8

*Reference ranges obtained from Heska hematology analyzer based on the age, sex of species
“j” means the value is shortage of reference range;
“I” means the value is excess of reference range.

5.4. Conclusion

GBM is the most common and aggressive brain tumor, with very poor prognosis 2.
Recently studies indicated that AR is considered as a potential therapeutic target to treat

GBM 38,63. In our previous study, compound I was identified as a promising drug
candidate for AR-overexpressed GBM, while it could suppress GBM in vitro and in vivo

by abolishing ARs 29.
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Based on the structure of compound I, a series of potential anti-glioblastoma
compounds were developed in this study. Both compounds 4 and 26 exhibited potent in

vitro anti-glioblastoma activity, including nanomolar level IC50s and AR downregulation

effects in GBMs, indicating that the anti-glioblastoma activity is similar to the lead

compound, compound I. As HSP27 inhibitors, both compounds 4 and 26 could inhibit α-

crystallin effect on insulin B chain aggregation, exhibiting potent HSP27 chaperone
activity inhibition capacity. It is well documented that HSP27 stabilizes AR and escorts it
translocating into nucleus, triggering ARE regulation and cell proliferation 74. Our

hypothesis is that both compounds 4 and 26 could induce AR downregulation via
inhibiting HSP27 chaperone activity. Compounds 4 and 26 could down regulate AR and
AR-V7 proteins in GBM cells, also the immunofluorescence assay results indicated that

AR level was decreased in nucleus mainly with the presence of compounds 4 and 26.
This result just solidified our hypothesis that the compounds induce AR degradation,

particularly abolishing AR translocation into the nucleus, by inhibiting HSP27 chaperone
activity. The in vivo study revealed that compounds 4 and 26 inhibit the U87 xenograft
and abolishes the AR in the tumor samples as well. Furthermore, the pharmacokinetic

studies indicated that compounds 4 and 26 could be distributed rapidly and be able to

cross blood brain barrier (BBB). Compared with compound I, these two compounds have
slightly higher permeability from blood into brain tissue, indicating that piperonyloyl and
2-Naphthoyl moieties are more helpful to cross BBB compared with 4-methoxyl benzoyl
moiety. Furthermore, these two moieties change from 4-methoxyl benzoyl moiety do not

exhibit any in vivo toxicity. Overall, this study indicated that compounds 4 and 26 could
be the promising drugs to treat AR over expressed GBM, also provided a meaningful
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insight for the further structural modification to retain or improve the potency and BBB
permeability.
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CHAPTER VI

CONCLUSIONS AND FUTURE DIRECTIONS

GBM is the most common and malignant primary human brain cancer with poor
prognosis and high mortality rate. It is reported that a higher incidence rate happens in
men compared to women, indicating that there is a sex disparity of the disease, which

may be correlated with different sex hormone pathways. Further studies revealed that AR

overexpression and mutation of AR are frequently observed in human GBM and
suppressing AR expression could induce GBM cells death in vitro and in vivo. It is well

known HSP27 is a chaperone protein that could stabilize AR. Targeting HSP27 to
downregulate AR becomes a novel approach for the treatment of AR overexpressed
GBM. We aimed to develop small molecule HSP27 inhibitor as potential drug candidates

to abolish AR in GBM, and mutated AR could be eliminated in this strategy as well,

which makes this approach superior to other anti-androgen compounds. Compound I

showed great potency and selectivity to inhibit AR overexpressed GBM cells. It inhibits

HSP27 chaperone function, and induces AR degradation, which is correlated to the
selectivity to AR overexpressed cells. The compound also inhibits tubulin polymerization,
therefore shows general activity to inhibit cell proliferation. Compared to a similar analog
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with an extra N-methyl group, compound I shows lower toxicity to mice. The removal of

N-methyl group does not bring the COX-2 inhibition back to the compound, suggesting
that after the reduction of the nitro group in the very lead compound nimesulide, the

COX-2 inhibition is eliminated in this scaffold. In addition to the HSP27 and tubulin
inhibition, compound I also affects AR transcription with an unknown mechanism, since

the mRNA of AR is also decreased after the treatment. It seems that the compound

suppresses AR in GBM with multiple mechanisms. The in vivo study reveals that
compound I inhibits U87 xenograft and abolishes the AR in the tumor samples as well

after the treatment. All the in vitro and in vivo activity demonstrate that compound I is a

promising drug candidate for AR overexpressed GBM.
To verify if compound I could cross blood brain barrier (BBB), a reliable and

sensitive HPLC-MS/MS method for the quantification of compound I in mouse plasma

and brain tissue was developed. The method was accurate, efficient, reliable, and

successfully applied for evaluation of the pharmacokinetics of compound I in the in vivo
study. The results indicated that compound I was rapidly distributed. Moreover,
compound I could across the BBB, which indicates the compound could be delivered to

the central nervous system. The pharmacokinetic profile summarized in the study

provides valuable information for the further investigation of compound I as a potential
anti-glioblastoma agent.

From the view of drug discovery, the structure of compound I was optimized, to
improve the potency of anti-glioblastoma. Based on the structure of compound I, a total
of 42 potential anti-glioblastoma analogues were synthesized in this study. Both
compounds 4 and 26 exhibited potent in vitro anti-glioblastoma activity, including
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nanomolar level IC50s and AR downregulation effects in GBMs, indicating that the anti

glioblastoma activity is similar to the lead compound, compound I. As HSP27 inhibitors,
both compounds 4 and 26 could inhibit α-crystallin effect on insulin B chain aggregation,

exhibiting potent HSP27 chaperone activity inhibition capacity. It is well documented
that HSP27 stabilizes AR and escorts it is translocating into nucleus, triggering ARE

regulation and cell proliferation. Our hypothesis is that both compounds 4 and 26 could

induce AR downregulation via inhibiting HSP27 chaperone activity. Compounds 4 and
26 could down regulate AR and AR-V7 proteins in GBM cells, also the

immunofluorescence assay results indicated that AR level was decreased in nucleus
mainly with the presence of compounds 4 and 26. This result just solidified our

hypothesis that the compounds induce AR degradation, particularly abolishing AR
translocation into the nucleus, by inhibiting HSP27 chaperone activity. The in vivo study

revealed that compounds 4 and 26 inhibit the U87 xenograft and abolishes the AR in the
tumor samples as well. Furthermore, the pharmacokinetic studies indicated that
compounds 4 and 26 could be distributed rapidly and be able to cross BBB. Compared

with compound I, these two compounds have slightly higher permeability from blood

into brain tissue, indicating that piperonyloyl and 2-Naphthoyl moieties are more helpful
to cross BBB compared with 4-methoxyl benzoyl moiety. Furthermore, these two

moieties change from 4-methoxyl benzoyl moiety do not exhibit any in vivo toxicity.

Overall, this study indicated that compounds 4 and 26 could be the promising drugs to
treat AR over expressed GBM, also provided a meaningful insight for the further

structural modification to retain or improve the potency and BBB permeability.
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However, the anti-GBM potency of compounds 4 and 26 is similar to the lead
compound I, even compounds 4 and 26 have higher HSP27 chaperone activity inhibition

effect. Furthermore, the new derivatives, compounds 4 and 26 have low BBB

permeability, which is similar to compound I. In the future, more structural optimization

is needed.
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